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ABSTRACT 
Study of canine cancer’s molecular underpinnings holds great potential for informing 
veterinary and human oncology. Sporadic canine cancers are highly abundant (~4 million 
diagnoses/year in the United States) and the dog’s unique genomic architecture due to 
selective inbreeding, alongside the high similarity between dog and human genomes both 
confer power for improving understanding of cancer genes. However, characterization of 
canine cancer genome landscapes has been limited. It is hindered by lack of canine-
specific tools and resources. To enable robust and reproducible comparative genomic 
analysis of canine cancers, I have developed a workflow for somatic and germline variant 
calling in canine cancer genomic data. I have first adapted a human cancer genomics 
pipeline to create a semi-automated canine pipeline used to map genomic landscapes of 
canine melanoma, lung adenocarcinoma, osteosarcoma and lymphoma. This pipeline also 
forms the backbone of my novel comparative genomics workflow.  
 
Practical impediments to comparative genomic analysis of dog and human include 
challenges identifying similarities in mutation type and function across species. For 
example, canine genes could have evolved different functions and their human orthologs 
may perform different functions. Hence, I undertook a systematic statistical 
evaluation of dog and human cancer genes and assessed functional similarities and 
differences between orthologs to improve understanding of the roles of these genes in 
cancer across species. I tested this pipeline canine and human Diffuse Large B-Cell 
Lymphoma (DLBCL), given that canine DLBCL is the most comprehensively 
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genomically characterized canine cancer. Logistic regression with genes bearing somatic 
coding mutations in each cancer was used to determine if conservation metrics (sequence 
identity, network placement, etc.) could explain co-mutation of genes in both species. 
Using this model, I identified 25 co-mutated and evolutionarily similar genes that may be 
compelling cross-species cancer genes. For example, PCLO was identified as a co-
mutated conserved gene with PCLO having been previously identified as recurrently 
mutated in human DLBCL, but with an unclear role in oncogenesis. Further investigation 
of these genes might shed new light on the biology of lymphoma in dogs and human and 
this approach may more broadly serve to prioritize new genes for comparative cancer 
biology studies. 
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Chapter 1  
INTRODUCTION 
1.1 Comparative Oncology Holds Significant Potential for Accelerating Cancer 
Drug Development in Humans and in Pet Dogs 
Cancer is the second leading cause of death in the United States. Cancer patients suffer 
from high mortality rates ranging between 1.1% for prostate cancer to 92.3% for 
pancreatic cancer within five years of cancer diagnosis (Z. Liu, Delavan, Roberts, & 
Tong, 2017). With about 40% of the drugs in clinicaltrials.gov being associated with 
“cancer and other neoplasm”, cancer targeting and drug development represents a 
significant portion of the biomedical field today. Experimental discoveries usually follow 
a path from the laboratory bench to preclinical animal studies and finally to testing for 
safety and efficacy in human subjects. However, most benchtop findings do not translate 
into practical clinical applications. As of 2017, among 5,154 clinical trials, 73% of the 
studies aimed to develop treatment options for cancer patients. These studies are in 
different clinical trial phases: 45% in Phase I, 53% in Phase II, 8.6% in Phase III, and 
only 0.6% in Phase IV. This clearly shows that many compounds enter Phase I and II but 
only a few make it to the last two phases (Z. Liu et al., 2017). Challenges in in vitro assay 
approaches, representative animal models and cancer drug resistance are the top factors 
attributed to higher failure rate in Phase III and IV.  
 
This chapter will focus on one of the three problems mentioned above – preclinical 
animal models. Despite successful animal studies, 85% of clinical trials for novel drugs 
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fail. Of those agents that proceed to Phase III, only half become approved for clinical use 
(Mak, Evaniew, & Ghert, 2014). An example of a trial that passed the animal model 
phase but failed in clinical trials is TGN1412, a immunomodulatory drug developed by 
TeGenero for applications in multiple sclerosis and cancer (Attarwala, 2010). This drug 
caused catastrophic organ failures in patients when administered at a sub-preclinical dose 
500-times lower than that was found to be safe in animals. Other examples of drugs that 
failed in early clinical trial phases are listed in Table 1.1. While logistic and design issues 
are frequently cited as the main cause for clinical trial failure, there are other reasons 
which are explained below (Mak et al., 2014).    
 
Table 1.1 Examples of Drugs that were Successful in Animal Models but Failed in 
Human Trials 
Animal	model	 Tumor	type	 Involved	
drug	
candidates	
Notes	
Cynomolgus	and	rhesus	monkeys	 B-cell	chronic	lymphocytic	leukemia	(B-CLL)	 TGN1412	(agonistic	anti-CD28	antibody)	
Severe	inflammatory	reactions	to	immune	system	in	Phase	I	Mouse	medulloblastoma	model	 Malignant	solid	brain	tumor	(medulloblastoma)	and/or	pancreatic	cancer	
Saridegib	(Hedgehog	pathway	antagonist)	
Lack	of	efficiency	compared	with	placebo	in	clinical	Phase	II	Mouse-derived	portion	of	scFv	on	chimeric	antigen	receptor	(CAR)	T	cell	
Acute	lymphoblastic	leukemia	as	well	as	relapsed	or	refractory	(r/r)	CLL	and	non-Hodgkin’s	lymphoma	
JCAR014	(a	CAR	T	cell	receptor,	targeting	CD22)	
Death	of	patients	in	a	Phase	I	dose-escalation	trial	
The table consists of drug trials that failed after successful testing in animal models (Z. 
Liu et al., 2017).  
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Several common reasons for drug development failures are described here. First, one of 
the problems with “targeted drugs” is while targeting mutations in single gene, often a 
feedback response cause by the molecular disruption can prevent the efficacy of the drug 
or it can actually increase the severity of the disease. Understanding such molecular 
responses is important for identification of effective combination treatments (Day, 
Merlino, & Van Dyke, 2015). Secondly, despite successful validation of novel anti-
cancer therapies in mouse models, most clinical trials fail because animal studies 
overestimate the likelihood of a treatment to be effective by 30% since negative results 
are not published (Reichert & Wenger, 2008). A third reason, most pertinent to my thesis 
studies, might be partly due to the animal model itself. Rodents are most commonly used 
as research animal models because they have short gestation times and are small. Thus, it 
is feasible to study multiple generations in a short time span. Also, there are many 
genomic technologies available to study the mouse genome and associated gene 
expression that are not as highly developed for other mammalian species. However, 
preclinical mouse cancer models are highly artificial. In the most frequently used 
approaches to mouse modeling of cancer, human cancer cells are grown subcutaneously 
in immunocompromised mice (xenografts) or, alternately, mouse tumors develop 
endogeneously under highly defined genetic contexts in transgenic strains with 
homogeneous genetic backgrounds. Further, the mouse strain selected for the study can 
greatly influence tumor penetrance and drug response. In many cases mouse tumors do 
not accurately recapitulate the essential features of naturally occurring human cancers 
such as cellular and molecular heterogeneity and the tumor microenvironment. The 
4 
 
tumors are induced by genetic and/or environmental manipulation, which means it cannot 
replicate the polygenic tumors in humans. Thus, mouse models miss a vast amount of 
genetic and environmental interactions that are present in humans (Rowell, McCarthy, & 
Alvarez, 2011). Additionally, artificially grown tumors in mouse and the natural tumors 
in human have inherent evolutionary differences (Lindblad-Toh, Wade, Mikkelsen, 
Karlsson, Jaffe, Kamal, Clamp, Chang, Kulbokas, et al., 2005). The overall poor clinical 
predictability of conventional in vivo cancer models highlights an obvious need for a 
detailed study of naturally occurring cancer in higher animal models like cats and dogs, 
to not only understand the biologic and molecular underpinnings of these cancers but also 
to evaluate their use as a model organism to study human cancers. 
1.2 Dogs – Our Best Friends in Sickness and Health 
Multiple important genomic, biologic, and physiologic arguments support dogs as 
powerful evolutionary models to overcome some limitations of mouse models and 
facilitate study of human diseases including cancer. First, their genomes are highly 
similar to human genomes. Dogs bear 39 pairs of chromosomes with 2.4 billion base 
pairs to the human 23 and 3.2 billion. Around 94% of the canine genome is arranged 
analogously to the human with about 5% of the actual genome sequence under purifying 
selection (i.e. highly conserved) between human and canine (Lindblad-Toh, Wade, 
Mikkelsen, Karlsson, Jaffe, Kamal, Clamp, Chang, Kulbokas, et al., 2005). Both the dog 
and human genome are predicted to contain approximately 20,000 protein-coding genes. 
Within breed, dogs are genetically homogeneous and known to have long regions of 
linkage disequilibrium, thereby reducing the overall number of markers required to study 
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their genomes for genetic association studies based on germline DNA sequences (Shearin 
& Ostrander, 2010). Further, the canine genome has been sequenced to greater than 7.6X 
coverage, which is a better assembly than other pets such as cats and is the best assembly 
besides that of the human (Lindblad-Toh, Wade, Mikkelsen, Karlsson, Jaffe, Kamal, 
Clamp, Chang, Kulbokas, et al., 2005).   
 
Second, their unique genetic architecture can be leveraged in unique ways to help inform 
understanding of disease biology in humans. Domesticated dogs have a large body size 
and have the most phenotypic diversity compared to other model organisms. For instance, 
the average weight of Chihuahuas and English Mastiff differs by approximately 65-fold 
(Rowell et al., 2011).  However, their genetic makeup varies significantly within versus 
across breed. Across breeds, dogs are relatively outbred in contrast to mice, an advantage 
when modeling the roles of genetic complexity in cancers, although with obviously less 
control over specific genetic contexts, particularly in the absence of well-defined canine 
cancer genome landscapes. However, purebred dogs have a unique population structure, 
with each breed arising from limited number of founders. Combined with the frequent 
use of sires for selective breeding, each domestic breed is a closed population with locus 
and disease homogeneity, making studies within-breed similar to those performed in 
isolated human populations like the Finns or Icelanders (Rowell et al., 2011). Inclusion of 
dogs from different breeds in genetic studies will provide background genetic diversity 
similar to human studies. This heterogeneity is not present to the same degree in inbred 
lab animals. Unlike mice, dogs share the same environment and are exposed to similar 
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carcinogens as humans. Shorter canine lifespan also allows us to study cancer 
progression in the course of a few years rather than the decades that often pass during 
which cancer quietly develops in humans (Breen & Modiano, 2008).  
 
Further, there are significant biological and physiological similarities between dogs and 
humans. For example the presence of similar telomere and telomerase activities and the 
frequency and spectrum of the development of spontaneous cancers are similar to that of 
humans (D. Liu et al., 2014). Dogs also often respond to drugs similarly to humans and 
hence they are routinely used in drug and toxicology studies. They also experience 
similar clinical phenotypes and outcomes (in the absence of intervention) as for many 
human diseases such as cancer. However, their disease course is often compressed with 
median overall survival for canine cancers being one year versus five years for all human 
cancers. Hence we can get comparatively rapid results from clinical trials in pet dogs 
(Hawai et al., 2013).  
 
Despite the above contexts in which dog studies may inform human studies, still little is 
known about the molecular underpinnings of cancer in dogs. Now, with the emergence of 
high-throughput genomic techniques, canine studies have defined these cancers better in 
dogs as well as in humans. For instance, canine studies have: 
1) Identified potential therapeutic targets shared by human cancers. For example, loss of 
heterozygosity in CDKN2A and CDKN2B has been described in soft tissue sarcomas of 
dogs. It has also been reported that deletion of these genes is observed in human cancers, 
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including soft tissue sarcomas, thus offering a novel target for discovering common 
pathways and genes that affect the disease progression in both species (Rowell et al., 
2011).  
2) Pointed to novel candidate cancer genes that were not previously identified in human 
cancers. For example: identification of PTPRJ in canine melanoma (Hendricks et al., 
2017). 
3) Identified causal genes in dog cancers that were previously underappreciated as drivers 
in human cancer. Example TRAF driver mutations in human lymphoma were identified 
by first discovering them in canine lymphoma (Bushell et al., 2015). 
 
An additional important advantage of comparative oncology modeling is that the 
opportunity exists to study up-front treatment of novel therapeutics in previously 
untreated cancers (Paoloni et al., 2014). Dogs have few established standard-of-care 
treatments. If the conventional treatments do not meet the goals of the pet owner, then 
novel therapeutic options including investigational drugs can be offered through clinical 
trials at any stage in cancer presentation (Paoloni et al., 2014). Hence personalized 
medicine interventions can be more rigorously evaluated over longitudinal stages of 
disease progression, which is not possible in human clinical trials. 
1.3 Genome, Phylogeny and Conservation 
The history of domestic dogs traces back 15,000 years during which they evolved 
through a mutually beneficial relationship with humans (Vilà et al., 1997). Over recent 
centuries, selective and preferential breeding of dogs has also produced diverse domestic 
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breeds. This diversification is advantageous for comparative geneticists in a manner 
similar to representing diverse races in human. Also, as a consequence of genetic 
homogeneity conferred by selective inbreeding for specific traits, some diseases show 
enriched breed-specific incidence (Elaine A Ostrander, Galibert, & Patterson, 2000). 
Over 360 genetic disorders in dogs have been identified. This is the largest set of 
naturally occurring diseases in any non-human species. At least half of these diseases 
resemble human diseases (E. A. Ostrander & Kruglyak, 2000). Thus canine genomes are 
predicted to be better models for studying the genetic basis of human diseases than other 
organisms.  
 
Pathologically and genetically, it has been shown that canines are good models. To 
substantiate the reasoning from an evolutionary aspect, related phylogenetic studies are 
explained in this section. Sequence analysis supported the traditional phylogenetic 
classification method, which was based on morphological features. But recent studies on 
mammalian phylogeny based on molecular analysis shows surprisingly different results 
from morphological classification (Springer, Murphy, Eizirik, & O'Brien, 2003). For 
example, Laurasiatheria is the superorder of placental mammals and the evolutionary 
clade to which Canis belongs, was discovered based on similar gene sequences shared by 
the animals belonging to it, the traditional method of phylogenetic classification. But 
molecular analysis shows that Laurasiatheria clade diverged from Euarchontoglires 85-
90 million years ago. Euarchontoglires subsequently diverged into Glires – rodents and 
Euarchonta – primates, roughly 80 million years ago. Thus, the approximate distance 
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between dogs and humans is 165 million years (Lunter, 2007). Though this distance is 
further from the rodents, rodents themselves later diverged from the same clade as dogs, 
thus increasing the total branch length between dogs and humans and thereby increasing 
the statistical power to search for conserved genes in human genome. A further 
confounding feature of comparative studies of mouse and human is that the mouse 
genome has been evolving faster relative to human and dog (Lindblad-Toh, Wade, 
Mikkelsen, Karlsson, Jaffe, Kamal, Clamp, Chang, Kulbokas, et al., 2005), which might 
lead to more species-specific mutations that could be less conserved.  
Knowledge of divergence age is important for understanding why some genomic regions 
are more conserved in one species over another. Hence, to understand the divergence of 
dog, human and mouse, the LIMA family, the youngest of the Long Interspersed Nuclear 
Elements (LINEs) that gave rise to most of the active species-specific LINEs, has been 
studied extensively (Kirkness et al., 2003). In the dog genome, relatively little DNA was 
classified as LIMA5-8 (in the order of age) and a lot more sequence as LIMA9. LIMA9 
might have derived from the early carnivore specific LINEs supporting the hypothesis 
that dogs diverged before human and mouse from the mammalian clade (Kirkness et al., 
2003).  This supports the view that the dog lineage was the first to diverge from the 
common ancestor of the dog, human and mouse. Hence, one could expect stretches of 
DNA that are conserved down the phylogenetic tree.  
 
Comparative analysis of human, dog and mouse by Kirkness et al. from The Institute for 
Genomic Research (TIGR) show more evidence highlighting closer sequence 
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conservation of dogs with human genomes than those of the mouse. The 1.5 fold 
coverage poodle dog sequences were aligned with human (GRCh31) and mouse (mm3) 
genomes to identify the best scoring alignments from the dog genome sequences. Almost 
twice as much of unique human sequences were aligned with dog than with mouse.  
Table 1.2 shows the percentage of genome alignment in every category to estimate the 
similarity among the species.  
 
Out of 29,673 human genes that aligned with dog sequences, 4% did not align with the 
mouse. It could be because these genes were more conserved between human and dog 
and could have mutated heavily while the mouse diverged, again, reinforcing that mouse 
mutated faster during evolution and conserved regions could be found in dog than mouse. 
 
Table 1.2 Comparison of Mouse, Dog & Human Genome Sequence Assembly by 
TIGR  
SIMILARITIES MOUSE-TO-
HUMAN 
DOG-TO-
HUMAN 
No. of genes 29,529 29,673 
No. of  transcripts 18,311 18,473 
% of protein coding transcripts 77% 61% 
% of similar genes that were aligned >50 
% 
93% 83% 
The human genome sequence was compared with the poodle sequence and the mouse 
reference genome. Number of best scoring alignments from each category is tabulated 
(Kirkness et al., 2003).  
1.4 Emerging Analytical Priorities for Enabling Comparative Oncology in Humans 
and Dogs 
As mentioned previously, biologically, genetically and evolutionarily, dogs are a better 
model organism than murine models to study about humans, but genomic analysis of 
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canine tissues faces several challenges. Predesigned and validated exome kits are 
available only for humans and mice while comprehensively validated WES kits for other 
animals, including dogs, are scarce (Broeckx et al., 2014). Only two canine exome kits 
are commercially available. Not only the genomic technologies but also the tools to 
analyze the data for dogs are not on par with humans and mouse.  
 
Kristen Linblad-Toh from Broad Institute and Manfred Grabherr from Upsala University 
spearheaded the canine genome assembly project. The first assembly was taken up as a 
two-year project, costing approximately $30 million. On the other hand, Human Genome 
Project took thirteen years and cost approximately $2.7 billion. The dog genome 
sequence was assembled from a Boxer breed with 7.6-fold WG shotgun assembly using 
the improved ARCHANE program resulting in first assembly – CANFAM1.0 in 2004, 
three years after the first draft of the human genome sequence (2001). An updated 
assembly with minor improvements, known as CANFAM2.0 was released in 2005.  The 
current version, CANFAM3.1 was released in 2011 has mitochondrial sequences from a 
dog breed different from the boxer – sapsaree family (NCBI, Nov 23, 2013). The key 
differences between CANFAM2 and 3.1 are given in the table 1.3.  
 
Table 1.3 Comparison of Canine Genome Assembly Versions 2 & 3 
PROPERTY CANFAM2 CANFAM3.1 
Coverage of euchromatic portion of the genome (%) 99.2 99.6 
Portion of the assembly in “certified” regions (%) 99.5 99.8 
Contiguity: Gaps per MB 12 6 
ENCODE regions High quality draft 98% finished 
Canine reference genome versions 2 and 3 are compared to show the improvements and 
accomplishments in the version 3 (Hoeppner et al., 2014).  
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Previous studies have identified the genomic make up of a few breeds, demonstrating that 
dogs from the same breed have similar common alleles (Irion et al., 2003; Koskinen, 
2003; Heidi G Parker et al., 2017; Heidi G. Parker et al., 2007; vonHoldt et al., 2010). 
But the latest version of dbSNP (build 139) has 80% of the SNPs from boxer or poodle, 
when there are nearly 400 modern domestic dog breeds with unique histories and lineage 
profiles. The SNPs in dbSNP are listed from all samples without individual lists limiting 
its usage in population analysis. With the rapid development of NGS technology, more 
than 250 whole genome sequencing analyses have been published as of now. Recent 
analysis of 1,346 dogs from 161 breeds using genomic SNP arrays revealed variations 
across breeds (Heidi G Parker et al., 2017). Recognizing the need to have a database of 
somatic variants and utilizing the above-mentioned information, DoGSD 
(http://dogsd.big.ac.cn) was developed in 2015 (Bai et al., 2015). This is the first database 
to focus on SNPs from domesticated dogs and grey wolves. The advantage of this 
database is that, unlike dbSNP139, which includes only variations from boxer and 
poodle, DoGSD includes SNPs reported from multiple source datasets covering 
numerous breeds.   
 
Generally, gene identification in eukaryotic organisms is difficult due to the small 
percentage of the DNA that encodes for protein, complex isoforms of the genes and the 
appreciation of the non-protein coding region. Gene identification in dogs is more 
complex due to low number of expressed sequenced tags produces and unsequenced GC 
rich regions in the untranslated region (UTR) and 5’ end of the genes (Derrien, Vaysse, 
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André, & Hitte, 2012). With the canine reference genome, the SNP collection from 
Lindblad-Toh (Lindblad-Toh, Wade, Mikkelsen, Karlsson, Jaffe, Kamal, Clamp, Chang, 
Kulbokas III, et al., 2005), and the recent DoGSD database, a considerable annotation of 
the canine genes has been done. To circumvent the above-mentioned challenges and to 
take advantage of the available information from disease association studies, genes are 
annotated using computational methods namely ab intio method and sequence similarity 
analysis amongst species. Because of the lack of functional canine data, my dissertation 
is focused on functionally similar orthologs based on evolutionary metrics.  
 
Finally, canine-specific and canine-validated informatics resources are limited. For 
example, many of the variant calling tools utilized for cancer genomic analysis, in 
general, are hardcoded for human sequences and require manual 
modification/customization of the source code. Some of the tools are listed below: 
1) Sequenza (Favero et al., 2015) –  a tool for calculating tumor purity,  
2) tCoNuT (TGEN, August 2016)– calls the copy number variations from tumor/normal 
samples,  
3) TOPHAT FUSION (Daehwan Kim & Steven L. Salzberg, 2011)- The fusion caller 
uses CanFam2, which is incomplete.  
 
Further, software and databases do not carry canine specific information. Some examples 
of such software/databases include:  
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1) IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-
pathway-analysis) – a pathway analysis and search tool for identifying new targets and 
candidate biomarkers from a biological systems context. 
2) MARRVEL(J. Wang et al., 2017)– Model organism Aggregated Resources for Rare 
Variant Exploration, a public resource for prioritizing variants in model organisms.  
3) polyPhen-2 (Adzhubei, Jordan, & Sunyaev, 2013) - a tool for predicting the functional 
effects of SNPs. 
4) ToppGene (J. Chen, Bardes, Aronow, & Jegga, 2009) -a gene list enrichment analysis 
and candidate gene prioritization based on the training list of genes. 
5) MINT (Chatr-aryamontri et al., 2007)– a database for protein-protein interaction 
mined from scientific literature. 
 
Even with the exponential development of the current informatics approaches, most of 
the annotation, interaction networks and functional information are simply translated 
from human or from yeast experiments rather being based on real biological data. There 
is clearly a dearth of resources for dogs, from sequencing technology to informatics tools 
and databases, when compared to the standard model organisms such as mice, yeast and 
Drosophila. The work in this dissertation is focused on addressing some of these 
informatics challenges by creating a working pipeline and applying it to multiple canine 
cancers like melanoma, lung adenocarcinoma and more. 
15 
 
1.5 Summary 
Realizing that canines are a potential resource to study human cancer based on 
evolutionary conservation, biological and genomic similarity, two distinct needs have 
been addressed in my thesis. First, the fundamental need for a genomics pipeline for the 
analysis of canine cancers has been addressed. Multiple tools were tested and made 
compatible to dog genome. The major caveat here is the lack of a standard golden dataset 
to validate the tools and their calls, which has been alleviated in part by experimental 
validation and simulation data. Second, bearing in mind the limitation of functional data 
and lack of a wholesale comparison of human genes with their orthologous dog genes, a 
systematic and quantitative review will provide insight into their role in cancer and other 
phenotypes. Here I have described a statistical logistic regression model developed to 
identify genes that are similar in both species. These two analyses will help bridge some 
of the gaps in canine informatics and also aid in better understanding of the canine 
genome and its utility for comparative oncology.  
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Chapter 2  
DEVELOPMENT OF A CANINE CANCER GENOMICS PIPELINE  
AND 
ITS DEPLOYMENT IN CANINE MELANOMA 
2.1 INTRODUCTION 
2.1.1 Analogy between Human and Canine Melanoma 
The value of comparative genomics is particularly apparent in the study of melanoma. 
With increasing incidence and poor five-year survival rates, human malignant melanoma 
is of great clinical concern (Maldonado et al., 2003). Mucosal melanoma (MM) is an 
aggressive melanoma subtype with an average age of incidence of 60 years and a five-
year survival rate between 12.3% and 35.3% (Manolidis & Donald, 1997; McLaughlin et 
al., 2005; Meleti et al., 2008). It occurs more commonly in women than men and is the 
most prevalent melanoma subtype in dark-skinned populations (McLaughlin et al., 2005). 
MM accounts for only 1-2% of human melanomas in the United States with as few as 
1,500 cases per year (Chang, Karnell, & Menck, 1998). The primary form originates from 
the mucosa of the sinus-oral cavity, anorectum, vulva and vagina. Due to its occurrence 
in occult sites and delayed signs and symptoms, the disease is typically diagnosed in 
advanced stages and the prognosis is poor (Mihajlovic, Vlajkovic, Jovanovic, & 
Stefanovic, 2012). MM is predominantly BRAF, RAS, and NF1 wild-type with occasional 
mutations in KIT or NRAS (Curtin, Busam, Pinkel, & Bastian, 2006; Curtin et al., 2005; 
Simon J Furney et al., 2013; Krauthammer et al., 2012; Maldonado et al., 2003; 
Manolidis & Donald, 1997; Meleti et al., 2008; Toshiyuki Tanaka et al., 2004; Turajlic, 
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Furney, Lambros, Mitsopoulos, Kozarewa, Geyer, MacKay, Hakas, Zvelebil, & Lord, 
2012). Being a rare lesion with low prevalence, it has been poorly characterized and 
incompletely understood in humans. 
 
On the other hand, malignant melanoma in canines accounts for up to 100,000 yearly 
cancer diagnoses in the United States with the most common subtype being the oral 
mucosal variant (Philip J. Bergman, 2007; Cotchin, 1955; S. Smith, M. Goldschmidt, & 
P. McManus, 2002; Villamil et al., 2011). Canine MM is also exceedingly aggressive 
with median survival being a mere 200 days (P. Bergman et al., 2006; Gillard et al., 
2014; Prasad, Patel, Huvos, Shah, & Busam, 2004; R Mark Simpson et al., 2014; 
Withrow, Vail, & Page, 2013). It has been found to resemble human melanoma both 
clinically and pathologically. However, little is known about its genetic etiology. 
Although known to be predominantly BRAF wild-type, targeted sequencing studies have 
shown that canine MM occasionally bears alterations in other known human melanoma 
drivers as well (Chu et al., 2013; J. Fowles, Denton, & Gustafson, 2015; Gillard et al., 
2014; Mochizuki, Kennedy, Shapiro, & Breen, 2015; Murakami et al., 2011; Poorman et 
al., 2015; Shelly et al., 2005; R Mark Simpson et al., 2014). Cytogenetic studies have 
shown some recurrent events with comparative relevance. For example, recurrent, 
complex somatic copy number aberrations in canine chromosome 30 (CFA30) are 
homologous to those seen on human chromosome 15 (HSA15) in human MM, suggesting 
similar genomic abnormalities driving MM in both species. (Poorman et al., 2015).  Also, 
immunohistochemistry staining has shown that the mitogen-activated protein kinase 
18 
 
(MAPK) and/or PI3K signaling pathways are activated in 52-77% of cases (Chu et al., 
2013; J. Fowles et al., 2015; Gillard et al., 2014; Murakami et al., 2011; Shelly et al., 
2005; R Mark Simpson et al., 2014). These data hint that there are similar alterations and 
pathways in MM in both organisms that could guide future biological exploration and 
therapeutic development. Alongside the general value of the study of naturally occurring 
canine cancers elucidated in Chapter 1, these features highlight the specific advantages of 
leveraging spontaneous canine MM in understanding rare BRAF wild-type and MM 
subtypes in dogs and humans (Paoloni & Khanna, 2008). However, in order to enable 
comparative genomic analysis of canine and human MM, we first must develop a canine 
cancer genomics pipeline. 
2.1.2 Constructing a Canine Cancer Genomics Pipeline 
Innovative informatics strategies are required as sequencing technology evolves and 
novel biological questions emerge. Current informatics strategies are well-suited for 
combining multiple layers of information to assist in understanding the molecular 
underpinnings of diseases like cancer. But with the development of cross-species 
genomic analysis, it is necessary to diverge from the conventional informatics analysis 
used for human patients since a species-specific pipeline will be able to cater to the 
informatics needs of the model organism and will also help in translating genomic 
information into biologically useful data. The significance of a well-structured pipeline 
can be understood from the Figure 2.1, where, apart from identification of variants, a 
series of steps are required to map a genomic variant’s functions into downstream 
phenotypes.  
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Figure 2.1 Cancer Analysis Pipeline 
The figure depicts different steps that are involved in analyzing the raw data from 
sequencer. It also shows the various disciplines, techniques and the challenges that 
are involved in each stage (Vazquez, de la Torre, & Valencia, 2012) 
2.1.3 Challenges with Canine Cancer Genomic Informatics 
Unlike human, there is neither literature on canines available where the variants called 
from Next Generation Sequencing (NGS) data have been validated with biological 
experiments nor a standard dataset like the 1000 genomes, a catalog of human sequence 
variants, to evaluate the performance of the informatics tools. This in turn leads to 
absence of a streamlined validated pipeline for canine, like Golden Helix 
(goldenhelix.com), GALAXY (Afgan et al., 2016), GENEPATTERN (Gould, Getz, 
Monti, Reich, & Mesirov, 2006) and many more for humans. Some of the challenges 
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with canine informatics include the existence of few canine-specific or species-agnostic 
tools, discrepancies between various annotation tools, unavailability of pure cell line data 
to quantify the results and gauge the performance of software or sequencing platforms, 
lack of whole exome sequencing (WES)/whole genome sequencing (WGS) raw data with 
deep coverage, etc. Currently, a little over twelve canine NGS studies comprising more 
than 250 tumors have been published. The analysis workflows used in each study varied 
dramatically and implemented different variant callers and parameters, especially for 
copy number and structural variants. For instance, Ryan Morin’s (Bushell et al., 2015) 
work on canine lymphoma called CNVs from SNP microarrays and not from sequencing. 
Elvers study (Elvers et al., 2015) used SegSeq to call CNVs, the disadvantage of which is 
explained in the following section. Also, the three-caller pipeline approach to call 
variants with improved detection of true positives is not yet implemented in canine 
sequencing workflows. Three-caller pipeline is necessary to call varinats with high 
confidence. In order to develop a robust, structured pipeline for canine cancer genomics, 
we first lifted over the peer-reviewed gold-standard human TGEN pipeline, PEGASUS 
(Liang et al., 2017; Manojlovic et al., 2017), to dog (Figure 2.2). Due to the above-
mentioned reasons, the original copy number and structural variation callers could not be 
used in the dog. Hence, I tested and implemented multiple copy number and structural 
variant callers to generate a semi-automated canine cancer genomic pipeline to study dog 
cancers.  
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My dissertation focuses on the challenges, function and implementation of only two types 
of variant callers, copy number and structural variant callers, since single nucleotide and 
INDEL callers were deployed with minor/no modifications. The upcoming sections will 
highlight the importance of these two variant types and explain the fundamental concept 
behind most of the tools available.  
 
Figure 2.2 Pegasus Pipeline – Human 
Pegasus is the in-house pipeline that is used to analyze the human samples that are 
WGS/WES. Both the genomic and transcriptomic steps are depicted in the 
figure(pegasus).  
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2.1.4 Copy Number Detection Methods 
Somatic cancer mutations can take multiple forms that are reflective of underlying 
mutagenic etiology: single point mutations and small insertions or deletions, gains or 
losses of whole chromosomes, chromosome arms, or focal chromosomal regions, or 
chromosomal rearrangements. Copy Number Variation (CNV), one of the somatic 
variations, is of major interest, as oncogene activation can be attributed to amplification 
and tumor suppressor inactivation can be attributed to deletion. Many significant efforts 
have pointed to the role of CNVs in cancer. For example, the deletion of CDKN2A in 
melanoma or the deletion of SMARCB1 in rhabdoid tumors (Meyerson, Gabriel, & Getz, 
2010; Shlien & Malkin, 2009; Weir, Zhao, & Meyerson, 2004) are both events critical for 
tumorigenesis in these tumor types. There are two important criteria in developing and 
selecting a tool to detect CNVs in any species: sequencing platform and the algorithm 
used for detection.  
 
It is important to note the method that was used to sequence the data, since WES 
introduces bias and noise due to hybridization of the probes to the fragmented genomic 
DNA sample, which do not exist with WGS data.  Hence, it is very important to identify 
a tool that works best for WES accounting for this bias. On the other hand, data from 
WGS is continuous and hence the tools should perform efficient normalization of the log 
ratios for longer regions of aberrations. There are few tools available that can call CNVs 
from both WES and WGS data. Hence, implicit modifications are required to make it 
compatible on both the platforms.   
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The method of CNV detection is critical and partially guided by sequencing technology. 
There are three major methods of detection: 1) read count, 2) paired end and 3) assembly 
approach (Zare, Dow, Monteleone, Hosny, & Nabavi, 2017). The read count approach, 
the most frequently deployed method, uses a non-overlapping sliding window to count 
the number of reads across the whole genome or the region of interest. Paired end 
estimates the distance between the paired ends of the reads. When the distance is 
different from the known or the assessed insert size, that region is predicted to have a 
genomic aberration. This method is mainly useful in studying structural variants like 
translocations. In the third approach, the short reads are assembled to the reference 
genome and the assembled reads are scanned for deviations from others. Paired end and 
assembly approaches are more suited for structural variations and WGS data. 
 
Due to the lack of availability of tools that could be implemented in both WES and WGS 
data, tCoNut (TGEN, August 2016) and ExomeCNV (Sathirapongsasuti et al., 2011a), 
tools based on the read count approach, were selected to assess their performance in 
canine data. These tools usually have two major steps 1) preprocessing and 2) 
segmentation. In the preprocessing step, noise and bias are eliminated by normalization. 
Segmentation, usually done by the circular binary algorithm (CBS) (Venkatraman & 
Olshen, 2007), is a procedure for merging the regions with similar read counts to form a 
CNV region, based on recursively localizing the breakpoint, thereby differentiating the 
copy number regions from the adjacent genomic regions.  
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2.1.5 Structural Variation Detection Methods 
Structural variations (SVs) are large chromosomal changes, defined by most tools as 
greater than 50 nucleotides in size, which result from chromosomal breakage and 
reattachment. Depending on the read pair information (paired read method of detection) 
they can be classified into five basic types: 1) insertion, 2) deletion, 3) duplication, 4) 
translocation and 5) inversion. The chromosomal events that would lead to four of these 
variations are explained pictorially in Figure 2.3. As the name suggests, insertion and 
deletion are the insertion and deletion of a part of the DNA sequence. Insertion of non-
self genomic sequence – like the hepatitis B virus, is termed as novel insertion. Similarly, 
duplication can be tandem or interspersed based on the position of the duplicated 
sequence relative to the original sequence. Translocation of a piece of DNA is termed 
inter-chromosomal when the deleted sequence appears in another chromosome and intra-
chromosomal when it is inserted at a different location in the same chromosome. Apart 
from these basic five types of structural variations, there are other complex genomic 
events like inverted duplication, unbalanced translocation and chromothripsis (Guan & 
Sung, 2016). Such large aberrations generally have biological implications, especially in 
cancer. For example fusion of the BCR and ABL genes to generate the BCR-ABL fusion 
has been associated with chronic myeloid leukemia (Nowell & Hungerford, 1960).  
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Figure 2.3 Types of Structural Variations 
Various types of structural variations and the mechanism by which they occur in 
the genome are shown. First line is the reference DNA strand without any variation 
and the second line is the example of the sample DNA with the denoted variation 
(Guan & Sung, 2016). 
Detection of SVs is centered on one of the two fundamental concepts – mapping-free or 
mapping-based approaches. Mapping-free techniques compare two samples to find any 
differences in the reads. On the other hand, mapping-based approaches identify abnormal 
reads in paired end samples. Mapping-based methods have three basic steps – 1) 
preprocessing, 2) SV discovery, and 3) SV verification. SV verification itself can be 
performed using either discordant pairs or split read analysis. SVdetect (Zeitouni et al., 
2010), a mapping-based tool, is explained here. The input BAM file is preprocessed for 
anomalously paired reads using the sliding window approach. SVs are detected by 
identifying the links, orientation, the paired end order, insert size and other user defined 
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parameters. Identified breakpoints are then visualized using Circos plots (Krzywinski et 
al., 2009). 
 
Tools like DELLY (Rausch, Zichner, et al., 2012) use integrative approach – combing 
short and long range paired end mapping and split read analysis for SV discovery to get 
better single nucleotide resolution. Discordant read pairs are binned and sorted based on 
the read pair orientation and coordinates, from which the genomic breakpoints are 
determined. Split read analysis method refines the break points based on fast k-mer based 
algorithm. Scores are computed based on those algorithms and the highest scoring 
regions are printed. Apart from utilization of a rigorous algorithm to identify the 
breakpoints, other advantages of DELLY over SVdetect are it analyzes every type of SV 
separately and filters the somatic and germline calls.  
2.2 METHODS 
The Cerberus pipeline analyzes paired tumor/normal DNA sequences generated from 
WES or WGS, identifies mutations, copy number aberrations and genomic 
rearrangements and annotates them. I have described the function, advantages, limitations 
and future work of this pipeline in upcoming sections.  
 
2.2.1. CERBERUS – Genomic Pipeline For Canines 
A human version of the pipeline was developed at TGen, tested and deployed on 
numerous samples (Liang et al., 2017; Manojlovic et al., 2017). This pipeline was 
modified to accommodate other species like canine, mouse, rat, etc., and the canine 
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version is called ‘CERBERUS’. Unfortunately, due to the reasons mentioned earlier, we 
could not liftover all the tools from human to dog. Recognizing the immediate need to fill 
the gaps, I completed the workflow by including new tools, modifying the hardcoded 
human software packages to accommodate dog genome and ensure the efficiency of the 
workflow. 
 
The workflow of the pipeline is described in Figure 2.4.  The pipeline takes FastQ file as 
an input, which are aligned to the canine reference genome version CANFAM3.1 using 
BWA mem (Li & Durbin, 2009). Aligned BAMs are sorted using Samtools (Li et al., 
2009) and duplicate reads are marked with PicardTools 
(http://broadinstitute.github.io/picard/). Post-alignment joint INDEL realignment and 
base score recalibration was done using GATK (A. McKenna et al., 2010). Somatic 
single nucleotide variants (SNV) are called using three callers, Seurat (Alexis 
Christoforides et al., 2013), Strelka (Saunders et al., 2012a) and muTect (Kristian 
Cibulskis et al., 2013), and the germline are called by Freebayes (Erik Garrison, 2012), 
Samtools and Haplotype Caller (G. A. Van der Auwera et al., 2013). The VCFs from 
each of these callers are annotated using SNPEff (P. Cingolani et al., 2012). A final list of 
mutations that were detected by at least two out of three independent callers is generated. 
Until this step, the human pipeline was lifted over to canine.  
 
Following SNV detection, CNV and SV detection tools were tested and implemented to 
complete the canine genomics pipeline. Description of the tools, their working and code 
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modifications are described in detail in my dissertation.  The tools were tested on two of 
the in-house canine melanoma samples- ND10_363 and ND10_441. ND10_363 and 
ND10_441 are acral and cutaneous melanoma from male and female cocker spaniel. This 
dataset was used because the samples have a matched normal sample, were sequenced 
using two types of WGS – Long Insert (LI-WGS) and short insert (SI-WGS). It was 
shown that using shallow LI-WGS with insert size of 900-1,000 base pairs increases the 
efficiency to detect copy number and structural aberrations compared to a shallow WGS 
with 300-400 base pair insert size (Winnie S. Liang et al., 2014). Also, the two 
independent sequencing libraries can act as replicates for assessment. The above two 
samples were selected since they are from the same breed of dog. Two samples were used 
to eliminate the possibility of sample variation. Therefore, the performance of the callers 
was assessed based on replication of the variant regions in both platforms, robustness, 
efficiency and species non-specificity.  
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Figure 2.4 Canine Genomics Pipeline - Cerberus 
Canine pipeline that was modified from the human pipeline is shown. The series of 
steps are alignment, INDEL realignment and recalibration, somatic and germline 
SNV, copy number and structural variant calling and annotation. Quality control 
metrics are obtained form the recalibrated BAM files.  
 
2.2.2 Copy Number Detection Tools 
To call the copy number variations, two tools, ExomeCNV (Sathirapongsasuti et al., 
2011b), and tCoNuT (TGEN, August 2016), were selected and tested based on at least 
two out of three of the following criteria: 1) should work with tumor/normal pair, 2) 
applicable to WES and WGS data and 3) based on the read count approach. tCoNuT was 
chosen based on the following analysis described below.  
DNA Aligner – CanFam 3.1 
 BWA -0.7.8 
Join INDEL Realigned  
GATK 3.3.0  
Somatic SNVs 
 
Seurat, Strelka 1.0.13, 
MuTect1.1.4 
Copy Number 
Variations 
 
tCoNut 
Structural 
Variations 
 
DELLY 0.7 
Annotation 
SnpEff -3.5 
Recalibrate, mark duplicates 
GATK 3.3.0  
Germline SNVs 
 
HC, Samtools 1.2, 
Freebayes 0.9.21 
Samtools stats 
Picardtools 1.128– MultiMetrics, 
HsMetrics, GCBiasMetrics  
CERBERUS Pipeline 
10 
Lift over from TGen’s human 
pipeline 
Different from TGen’s human 
pipeline 
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2.2.2.1 ExomeCNV 
ExomeCNV is specifically designed for detection of somatic CNV from WES data. It 
counts the reads in the exonic region of the tumor and normal samples, and a ratio of 
tumor to normal read count is computed. ExomeCNV has many advantages: 1) log ratios 
are adjusted to given tumor purity, 2) LOH can be calculated and 3) the average read 
count per exon is normalized by overall exome average count. The only drawback of this 
tool is that it cannot be extended to WGS since it is a tool that is specialized to call CNVs 
from exome seqeunced data. ExomeCNV has the highest sensitivity using human data, 
when compared to other latest CNV detection tools – Table 2.1 (Sathirapongsasuti et al., 
2011a; Zare et al., 2017).  
Table 2.1 Comparison of Copy Number Callers  
Method ADTEx CONTRA cn.MOPS ExomeCNV VarScan2 
Amplification 
Sensitivity 51.53% 54.37% 58.03% 83.67% 69.11% 
FDR 33.70% 53.52% 57.36% 38.79% 26.87% 
SPC 89.84% 83.06 66.54% 82.07 92.71% 
Deletion 
Sensitivity 50.14% 64.95% 52.81% 82.94% 76.77% 
FDR 41.80% 64.86% 61.35% 45.31% 51.91% 
SPC 94.18% 78.86% 78.08% 87.26% 82.52% 
Multiple copy number detection tools, specialized for WES data were evaluated for their 
performance. ExomeCNV has higher sensitivity and specificity compared to the other 
tools in the list (Zare et al., 2017).  
 
2.2.2.2 tCoNuT 
tCoNuT, TGen’s Copy Number tool, is an in-house copy number identification tool based 
on read count approach. It requires tumor and a matched normal or a control sample to 
calculate the change in read depth. The advantage of this tool is that, it can be used with 
WES or WGS data and can calculate LOH from B-Allele Frequency (BAF), thus, an 
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obvious choice for a robust pipeline. tCoNuT requires Perl, R and MATLAB Compiler, it 
is designed to accommodate WES, WGS and aCGH data and uses BAMs as an input. 
The segments are re-centered using annotated heterozygous SNVs from Haplotype 
Caller. Other user-defined parameters are smoothing window size, threshold for log fold 
change, minimum distance between two consecutive segments and depth of tumor and 
normal sample. These parameters were modified to suit the canine genome. Comparison 
of tCoNut and ExomeCNV is given in table 2.2. 
Table 2.2 Comparison Of ExomeCNV and tCoNuT 
PARAMETERS ExomeCNV tCoNuT 
Normalization of Log Ratios based on tumor purity ✓  
Application in WGS and WES  ✓ 
Detection of LOF and BAF ✓ ✓ 
Segment normalization ✓ ✓ 
Re-centering based on heterozygous SNVs  ✓ 
Species agnostic ✓  
Parameters that were considered to select the tools for testing canine samples are listed.  
 
tCoNuT, like many other tools, is hard-coded for human but thoroughly tested for human 
aCGH, WGS and WES data. Considering the tool can be customized to suit canine by 
modifying the above-mentioned parameters and its multi-platform applicability, tCoNuT 
was selected. Thus, the source code was downloaded from Github, modified and 
recompiled to turn it as a canine-compatible program. Apart from replacing the reference 
genome and GTF to canine’s, modifications [1][2]in the code include accounting for the 
increase in the chromosome, altering the segmentation ratio in the CBS algorithm and the 
duplication and amplification identification threshold based on the purity metrics and the 
heterozygous variants (if available). Also, the built-in source code for plotting the graphs 
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was replaced with custom R script to plot LOH, BAF and segmented copy number values 
for all the 39 pairs of chromosomes. Tailor-made canine-specific tCoNuT was tested with 
canine melanoma samples and is now being implemented in many WES and WGS cancer 
samples.  
2.2.3 Structural Variation Detection  
From the fundamental methodologies of SV detection described above, it is evident that 
the tools are inherently species agnostic. Hence, there is a larger pool of SV detection 
tools to pick from compared to copy number. Two tools – SVDetect and Delly were 
selected based on their algorithm. LI-WGS has the ability to detect SVs at lower 
coverage and SI-WGS being the frequently used method of sequencing, the tools were 
evaluated based on the concordance of calls on both platforms.  
2.2.3.1 SVDetect 
SVDetect requires Perl and listed dependent modules to be installed prior. BAM files are 
preprocessed to calculate the mean (mu) insert size and stand deviation (sigma) from the 
distribution of the normally mapped reads. Mu and sigma values are used to detect 
abnormal reads. Another BAM file with only abnormally paired reads is generated and is 
used in the downstream analysis. Computation time is reduced by a large factor since 
only the abnormal reads are used thereafter, and consequently, even deeply sequenced 
samples can be run faster, with less cores and memory.  Sliding window size, a user-
defined parameter is an important factor determining the efficiency of the tool. Hence, 
the optimal window size is calculated using the formula 2*mu + 2*sqrt(2)*sigma and 
step length takes a fourth of the window size. A config file containing these values, the 
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location of file, read length, number of threads is created for every sample. An advantage 
of using SVDetect is that it can create Circos plots just by including the command in the 
config file. Conversely, the disadvantage is that it cannot identify small variations or 
filter the somatic or germline variants. Stringent filtering criteria were used to reduce 
false positive calls.  
2.2.3.2 DELLY 
DELLY requires sorted, indexed and duplicate-marked BAM files, an indexed reference 
genome and a sample list labeling the tumor and normal samples. Since, it works on split 
read analysis and paired end mapping, it is necessary to ID the read groups accurately. 
DELLY supports both germline and somatic SV calling. The output is generated as BCF 
file that is then converted to VCF using BCFTools (Li et al., 2009). It computes coverage 
and insert size from the BAM file rather than being given as a user-defined parameter, 
which is an added advantage. A SLURM script was written [3][4]to call SVs, filter the 
germline variants and convert the BCF file to VCF. The final results were further filtered 
for high coverage regions (those with a minimum depth of twelve reads), and the 
breakpoints near the centromere were discarded. This filtering step minimized the false 
positive rate. Resulting VCFs were annotated and visualized using Circos plots.  
2.3 RESULTS  
All the tools were run on two melanoma samples ND10_363 and ND10_441. The results 
were assessed based on the efficiency and concordance from both LI-WGS and SI-WGS. 
Such multiplatform analysis and cross validation should compensate for the lack of a 
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standard truth set. A launcher Bash script was written to streamline and semi-automate 
the pipeline. 
2.3.1 Structural Variation Caller – DELLY performance better than SVDetect 
Abnormally paired reads from tumor and normal sample generated from preprocessing 
step was used to call the structural variants. The results are tabulated in Table 2.3.  From 
the table we can see that SVDetect calls an enormous number of somatic variants, in the 
order of 1x105 with default parameters. These calls were filtered based on two conditions: 
1) the variations should be unbalanced and have a perfect score of 1 and 2) at least one of 
the two regions should fall in the ENSEMBL annotated gene. Concordance is calculated 
as the number of breakpoints that are present in both the LI-WGS and SI-WGS of the 
same sample. Due to the presence of large number of calls, coupled with the 
unavailability of a standard truth dataset, it is difficult to accurately evaluate this tool. 
Hence I opted for a better algorithm and more stringent parameters to call structural 
variants in canine samples.  
Table 2.3 SVDetect: Comparison of SVs from LI-WGS &SI-WGS 
SAMPLE 
ID 
#EVENTS WITH 
DEFAULT 
PARAMETERS 
#EVENTS 
AFTER FILTER 
1 
#EVENTS 
AFTER 
FILTER 2  
 LI SI LI SI LI SI 
#EVENT
S IN LI 
&SI 
ND10_363 1549529 1012266 1143032 905781 468098 434201 21604 
ND10_441 1534662 984739 1134959 910938 532414 450200 22452 
The table consists of two selected samples, number of genes that were called with default 
parameter setting, after applying filter 1 and 2. The last column shows the number of 
genes that were called by SVDetect in both LI-WGS and SI-WGS  of the same sample. 
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DELLY, the second tool was run through the same set of samples with default 
parameters. Unlike SVDetect, there is no preprocessing step for DELLY.  The tumor and 
normal BAM files were compared with the canine reference- CANFAM3.1 to call all 
types of SVs, which were then filtered to get the somatic variants. Since, it is based on 
both paired and split read analysis, the false positive rate is lower. SVs with a split read 
support of greater than twenty and containing at least twenty reads in the variant pair 
were then selected. From Table 2.4, we can see that sample ND10_363 has perfect 
concordance. 
 
Table 2.4 DELLY: Comparison of SVs from LI-WGS &SI-WGS 
SAMPLE 
ID 
#GENES WITH 
DEFAULT 
PARAMETER
S 
#GENES AFTER 
FILTER 1 
#GENES AFTER 
FILTER 2 
 
 LI SI LI SI LI SI #GENES 
IN LI &SI 
ND10_363 817 385 9 9 9 9 9 
ND10_441 375 260 39 34 16 15 9 
The table consists of two selected samples, number of genes that were called with default 
parameter setting, after applying filter 1 and 2. The last column shows the number of 
genes that were called by DELLY in both LI-WGS and SI-WGS  of the same sample. 
 
SVDetect uses on average 2.5 hours to compute the variants after the preprocessing step. 
But preprocessing is the longest step and uses on an average five hours. On the other 
hand, DELLY requires four hours of time in total. Though based on computing time and 
resources, both are similar, based on the confidence and concordance of the calls, 
DELLY performs better than SVDetect for canine samples.  
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2.3.1.1 Advantages and Disadvantages of SVDetect and DELLY 
Delly is robust in that it uses an integrated approach to call breakpoints. It refines calls 
based on tumor purity and can separate germline and somatic calls. The disadvantage is 
that it cannot call complex variations and insertions accurately. On the other hand, 
SVDetect has a higher false positive rate, longer computational time and cannot call 
small insertions and deletions although it can call complex variations like inverted 
translocations.  
2.3.2 Copy Number Variation Caller Comparison and Evaluation 
Though ExomeCNV performs equally well with WES data, it cannot handle WGS. From 
a review on tools for detection of CNV from WGS (Pirooznia, Goes, & Zandi, 2015), we 
know that there are not many tools that could perform CNV analysis using read count 
methodology. Here is the list of tools that were tested with the canine samples but failed 
due multiple reasons.  
1. SVDetect: Since this is based on read mapping technology, it was able to identify 
the regions and provide only density scores instead of log ratio. Also, these 
density scores were not normalized. Finally, as pointed earlier, it has a high false 
positive error rate.  
2. Control-FREEC(Boeva et al., 2012): This is another tool that works very well 
with WGS and WES data but is hardcoded for human. There are few 
specifications that needed modification to run through non-human organism. The 
two major specifications are requirement of a chromosome length file and 
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telocentromeric regions. The latter is not available for dogs affecting centering 
and identification of the CNV regions. Hence this tool was dropped.  
3. SegSeq (Chiang et al., 2009): Based on Poisson distribution of read density. This 
method assumes that the reads are uniformly distributed across the genome, which 
does not hold true in most of the situations. But the algorithm is powerful. It 
combines the local change points with subsequent merging to join the adjacent 
chromosomal regions. The merged segments were then be tested for significance 
across tumor and normal samples. This algorithm is powerful except that it 
involves significant computational burden and also loses statistical power when 
performed across tumor samples, as normalization is localized to samples (Ding, 
Wendl, Koboldt, & Mardis, 2010). SegSeq addresses the loss of power by using 
population-based correlation matrix diagonal segmentation. The biggest 
disadvantage of this tool is that – for humans, the parameters were set based on 
replicates lanes of the normal samples. My cohort did not have replicate lanes to 
set the parameters for dogs.  
 
Due to the lack of tools and applicability to canine, the well tested TGEN’s CNV caller 
tCoNut was modified for dogs. Similar to the SV analysis, tCoNuT was run on two 
samples for both LI-WGS and SI-WGS and assessed for concordance. In Sample 
ND10_363 CNVs with log ratio of either >0.5 or <-0.5 were filtered. These events fell in 
32 and 53 genes in LI-WGS and SI-WGS respectively, of which eleven genes with a 
copy number alteration were present in both platforms. Concordance of copy number 
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alterations were further checked with other genomic platforms, namely aCGH and 
SNPArray. The results of those can be found in detail in appendix V. 
2.3.3 APPLICATION OF CERBERUS PIPELINE IN COMPARATIVE 
MELANOMA STUDY  
The Cerberus pipeline was implemented in the comparative study of human and canine 
melanoma (Hendricks et al., 2017). The genomic landscape of canine melanoma was 
established with multiplatform analysis. We identified novel predominant truncating 
mutations in the putative tumor suppressor gene PTPRJ in 19% of cases, MDM2 
amplification and TP53 mutations.  
 
A median of 27 focal CNVs were identified using tCoNuT from the cohort of seven 
canine mucosal melanoma samples. We also observed high platform concordance 
(overlapping regions of red/blue in the bottom three rows) with the CNV obtained from 
SNP Array and aCGH microarrays (Figure 2.5). Many of the amplifications and deletions 
were present in the all the three platforms in these two samples. From GISTIC (Mermel 
et al., 2011) analysis, significant amplifications were identified in the MDM2 and CDK4 
regions. We also identified homozygous deletion in CDKN2A and focal amplifications in 
KIT. Between 9 and 65 SVs, predominantly inversions were identified from the same set 
of samples using DELLY (table 2.5, APPENDIX 1). Though there were no recurrent 
alterations, CFA10 rearrangements were found in five of seven cases, four of which bore 
significant CNV alteration from GISTIC analysis. 
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The most significant findings are the TP53 mutations and MDM2 amplification in these 
canine samples. Truncating mutation of TP53 and amplification of MDM2 are key routes 
to p53 inactivation. Though this set of variation is less common in human melanoma, 
four of the canine cases had at least one of these. Hence, this finding highlights the 
difference of canine MM, as well as sheds light on human melanoma. Apart from canine 
melanoma, the pipeline is being actively implemented in the study of lung 
adenocarcinoma and osteosarcoma.  
Table 2.5 Somatic SVs Identified in The Discovery Cohort of Canine Melanoma 
Genomic 
Coordinates 
Region 1 
Genomic 
Coordinates 
Region 2 
Rearrangement 
Type Gene(s) Affected 
10:3899883 10:3901435 Deletion SLC16A7-SNORA31 
30:3176840 30:12299361 Deletion 
ENSCAFG00000008403-
C15orf41 
30:14222475 30:15582006 Deletion SEMA6D-SLC24A5 
30:15581953 30:15607049 Deletion FAM227B 
30:21928641 30:22738088 Deletion ZNF280D 
30:12182424 30:23783769 Duplication SQRDL-7SK 
30:15579615 30:23175033 Duplication FAM227B 
30:15060828 30:15607811 Inversion SHC4 
30:20882843 30:22561457 Inversion DYX1C1-PYGO1 
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Figure 2.5 Concordance of CNV From Multiple Platforms in Canine Melanoma 
Discovery Cohort 
CNV calling concordance between LI-WGS and SI-WGS, Agilent aCGH and 
illumine SNP platforms is represented in the graph. The chromosomes are 
represented along the top with the sample IDs, percentage of amplification in blue  
and deletion in red. Events from individual platforms as separate rows (SNP,aCGH 
and WGS).  
Detailed implementation of the CERBERUS pipeline in canine mucosal melanoma and 
the landscape is given in APPENDIX V. 
2.4 CONCLUSION 
Due to a lack of availability of species-nonspecific tools, most of the tools or software 
were modified and tweaked to run canine samples. This raises an immediate need for 
species agnostic tools. Also, there is a deficiency of standard reference set to validate the 
results and evaluate the callers. Most of the simulators cannot effectively handle SVs and 
CNV. In the case of CNV callers, there is a serious dearth of WGS callers, let alone 
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species specificity. In spite of these difficulties a fully functional genomic pipeline 
specific for canines is created and put to active use. These tools will be updated and 
replaced with the availability of better tools and software and functional data for 
evaluation.  
 
Further, the pipeline will be improved by identifying a better annotator. SNPEff, the 
standard annotator, does not annotate the protein changes accurately. We have observed 
either missing protein annotation or incorrect ones in a few cases, raising questions about 
its validity in non-human species. Hence other tools like Variant Effect Predictor (VEP) 
will be tried. Future work will involve evaluation and implementation of RNA pipeline.  
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Chapter 3  
A NOVEL COMPARATIVE CANCER GENOMICS WORKFLOW BASED ON 
EVOLUTIONARY METRICS 
& 
ITS APPLICATION IN CANINE AND HUMAN DIFFUSE LARGE B-CELL 
LYMPHOMA (DLBCL) 
3.1 INTRODUCTION 
3.1.1 Function-Oriented Orthology in Comparative Genomics 
One of the problems in genomic analysis, especially cross-species cancer analysis is the 
mutation function annotation. Important cancer mutations (and cancer genes) are 
identified by analyzing patterns of mutation, mutation frequency, gene structure and 
annotation in genome landscape studies, and available experimental data (like mouse 
models with engineered mutations or cell lines, etc.) to link those specific mutations to 
phenotypes. However experimental data is not available for all genes. Thus, it becomes 
difficult to prioritize such genes with low frequency mutations. Furthermore, as pointed 
out in chapter 1, the gene annotation in dogs is worse and lesser functional data is 
available. In an attempt to improve our understanding of gene and mutation link to cancer 
phenotype, I have implemented an orthology based cross-species workflow.  
 
Orthologous genes are homologs between species that have evolved from the same last 
common ancestor after speciation whereas paralogous genes are homologs within the 
species that arise by duplication. Homologs share an arbitrary sequence similarity 
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threshold - a qualitative term defining the degree of sequence match between two 
compared gene sequences which is popularly used in comparative genomic studies. 
Comparative genomics is the study of genomes from different species specifically 
analyzing similar regions in the genome (homologs) to understand the evolution of the 
species and the functions of genes. Comparative study of genes have indicated that there 
is a strong role of selection pressure working on the genomes (Zapilko & Korsching, 
2016). Selection pressure is the force that retains, modifies or deletes the functioning of a 
gene through the evolutionary tree. Researchers have identified the roles of genes by 
comparing the sequence conservation between species coupled with the timing of the 
evolutionary events. If a gene is preserved down through a few clades in the phylogenetic 
tree with high sequence similarity and a very few duplication events, it can be inferred 
with high confidence that the gene and its ortholog might have similar function (Koonin, 
Mushegian, & Bork, 1996).  This method of studying the functions of a gene or protein is 
termed as function-oriented orthology.  
 
A good example of this orthology-function hypothesis is the function of CLCN5 in 
human and mouse. In humans, a SNV in this gene is associated with several phenotypes 
like proteinuria, hypercalciuric nephrocalcinosis, dental diseases and nephrolithiasis-
type I. The orthologous gene Clcn5 in mouse is associated with similar type of diseases 
like; increased urine protein level (proteinuria), abnormal renal protein reabsorption, 
(nephrocalcinosis) and abnormal tooth development. The orthologous genes share the 
same domains and have a sequence identity of 97%. The close relationship between 
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sequence and phenotype similarity shows that the orthology has a potential to be used for 
gene-phenotype association (P. Wang et al., 2013). Two major goals in study of the 
function of a gene, are: 1) delineating genealogy of the genes to study the evolutionary 
mechanism and 2) group the genes with similar biological function (Fang, Bhardwaj, 
Robilotto, & Gerstein, 2010). Thus by identifying the orthologs based on function, we 
can detect the role of a gene in a species. Besides the above-mentioned uses, study of 
orthology is important in annotating the genes in a newly sequenced genome, pathway 
comparison and its predicted phenotype and in drug administration. Drug repositioning of 
Parkinson’s disease has been established recently by studying the mouse phenotypes (Y. 
Chen, Cai, & Xu, 2015). Hence, it is very important to study and identify genes that work 
similarly in two species. 
 
Therefore study of orthologous genes to predict the function of a gene and associating the 
mutation to a phenotype is a major part of comparative genomic analysis.  We know that 
dogs are good models for cancer studies, but there is neither a well-characterized 
genomic landscape of canine cancers nor a completely curated gene functional database 
available. I am using orthology-based methods to perform cross species analysis. 
Defining methods and creating tools for accurate identification of orthologs and paralogs 
is a problem and a study of its own. Similarly, the use of homology studies in 
comparative biology to identify genes with similar function and phenotype presents 
significant challenges.   
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In my approach, genes with similar functional (tumor) activity in dogs and humans are 
identified by using both as query organisms to get various factors like, sequence 
similarity, synteny and others. These bi-directionally similar genes will form a good 
candidate set to study expression patterns and phenotype when perturbed. These genes 
can help in establishing a relationship between phenotype and diseases in humans by 
analyzing the same in the model organism (Cho & Hofmann, 2004; Singh et al., 2009). 
Hence, based on the genotype-phenotype theory and function-oriented orthology, I have 
developed a statistical method for predicting whether an orthologous gene in a non-
human species is likely to be a good model for tumor activity in the human, based on 
evolutionary conservation. In order to identify such genes, a workflow is created using 
DLBCL data as the input and multiple evolutionary metrics are used to estimate the 
similarity. DLBCL dataset is the largest canine WES sample available publicly. This 
dataset consists of 64 tumor/normal matched samples from 2 breeds of dogs – 10 Cocker 
Spaniel and 54 Golden Retriever samples 
3.1.2 Diffuse Large B-Cell Lymphoma (DLBCL) 
Non-Hodgkin Lymphoma (NHL) is a biologically and clinically heterogeneous group of 
lymphocytic cancers typically arising in lymphoid tissues. Primary NHL sub-
classification follows cell of origin and so includes B-cell or T-cell lymphoma with many 
diverse subtypes occurring in both categories. Diffuse Large B-Cell Lymphoma in 
humans (hDLBCL) is the most common subtype, accounting for 31% of NHL in most 
Western countries (Martelli et al.) (figure 3.1). It is an aggressive cancer with 
approximately 30,000 new diagnoses in the United States every year (M. A. Chapman et 
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al., 2011; Drake et al., 2010). The standard of care is chemotherapy and anti-CD20 (a B-
cell marker) antibody therapy (Drake et al., 2010; Qi et al., 2009).  Canine DLBCL 
(cDLBCL), similar to human NHL, is a predominant subtype of canine NHL (Figure 
3.1). cDLBCL  commonly occurs in pet dogs as an aggressive tumor showing moderate 
to severe enlargement of peripheral lymph nodes. Depending on clinicopathological and 
morphological characters, dogs with cDLBCL exhibit a variable course and response to 
treatment and prognosis(Aresu, 2016). cDLBCL shares similar morphological features 
and histological markers such as CD20 with humans. The most common treatment is R-
CHOP chemotherapy as administered to hDLBCL (Richards et al., 2011). With greater 
than 50% of human patients experiencing a poor outcome, there is a need to consider for 
better animal models that would accurately mimic the hDLBCL and improve the 
therapeutic options.  
 
Figure 3.1 Comparison of Canine and Human Prevalence in NHL Subtypes  
The two pie charts show the prevalence percentage of different types of NHL in 
canine and human. In both species, DLBCL is the predominant sub-type(Richards 
et al., 2011) 
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3.1.3 TCGA Data and its Workflow 
The Cancer Genome Atlas (TCGA), a consortium that houses genomic, transcriptomic, 
clinical, epigenetic  and clinical data from multiple cancer types. TCGA, supervised by 
National Cancer Institute’s (NCI) Centre for Cancer Genomics (CCG) and National 
Human Genome Research Institute (NHGRI) has its Genome Characterization Center 
(GCC) for sequencing and Genome Data Analysis Center (GDC) to perform 
bioinformatics analysis. GDC’s DNA sequencing pipeline is used to call somatic single 
nucleotide variants (GDC). It is important to understand the working of the TCGA 
pipeline, since its data is widely used in many studies, including my analysis.  
 
The TCGA pipeline consists of the following components (Figure 3.2): BAM files 
submitted to the GDC are split by read groups and then converted to FASTQs. These files 
undergo a quality control step and are then aligned to the reference genome, GRCh38, 
using BWA-mem (Li & Durbin, 2009). This reference genome includes ten types of 
decoy human viral sequences included in it.  After alignment, the BAM files are INDEL 
Realigned (G. A. Van der Auwera et al., 2013), base-score-recalibrated and then variants 
are called using 4 callers – MuSe (Fan et al., 2016), Varscan2 (Koboldt et al., 2012), 
MuTect2 (Kristian Cibulskis et al., 2013) and Somatic Sniper (Larson et al., 2012). The 
VCF files are then annotated using Variant Effect Predictor (VEP) (McLaren et al., 2016) 
and all the annotated VCFs from a single caller for all patients are aggregated together 
into distinct MAF files, which are then made available publicly.  
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Figure 3.2 TCGA Genomic Variant Identification Workflow 
TCGA genomic pipeline is shown as a flowchart. The pipeline uses GATK tools for 
alignment and cleaning, which is similar to the CERBERUS pipeline (GDC) 
 
3.1.4 Cancer Genes are Uniformly Significantly More Conserved than the Rest of 
the Genes in Dogs and Humans   
There are 21,363 and 17,239 ENSEMBL genes that are annotated in human and dog 
respectively. A general estimate of distribution of translated amino acid similarity 
between dog and human will give a basic idea of about the conservation of orthologous 
genes in humans. Hence, the ENSEMBLE annotated genes, only one-to-one orthologs 
were filtered resulting in 15,319 and 14,664 human and dog genes. Percentage of 
translated amino acid sequence similarity for those genes were plotted (Figure 3.3).  0.7% 
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(110) human genes and 1.7% (267) dog genes had less than 40% sequence similarity, 
showing that most of the human genes share at least 40% sequence similarity to dog 
genes. DUX4 is only the gene associated with cancer (based on the presence in the 
COSMIC database) that had less than 40% similarity.  
 
Figure 3.3 Boxplot Showing The Distribution of Amino Acid Similarity in Dog and 
Human Genes 
ENSEMBL annotated human genes were filtered for one-to-one orthologs and 
grouped into two classes – dogs and humans. The percentage of translated amino 
acid sequence similarity of the genes for the groups is represented. X-axis represents 
the species – dog and human and the Y- axis shows the percentage of translated 
amino acid similarity between the two species.  
 
The above analysis, for the first time identified that essentially all (718/719) known 
cancer associated genes in human (from COSMIC cancer census database) has at least 
40% sequence similarity. This key observation led to the central hypothesis that the mean 
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conservation of cancer-associated genes in human to dogs is more highly conserved than 
the remainder of all orthologous genes. Welch’s T-test was performed to test this 
hypothesis. ENSEMBL annotated orthologous human genes were separated into two 
classes – those that are known to be associated with cancer as ‘cancer’ group and the rest 
as ‘non-cancer’ group containing 629 and 14690 genes respectively. For these genes 
translated amino acid sequence similarity was obtained and the distribution was plotted as 
boxplot (figure 3.4). Two-sided T-Test resulted in a significant p-Value of  <2.2e-16 with 
sample estimates of cancer and non-cancer group as 90.14 and 85.2. Supplementing the 
T-test, random permutation was performed 100x by sampling a random set of 629 and 
14690 genes from the original dataset and performing the T-Test.  The distribution of p-
Values over 100 times of the permutation test is shown in figure 3.5. Out of 100 p-values 
none were equal to the value obtained from the T-Test (least value is 0.00644). This 
strongly suggests that the results we obtained were not by chance, and of great interest, 
the genes associated with cancer appear more conserved more than the remainder of 
human genes.   
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Figure 3.4 Distribution of Amino Acid Similarity in The Human Genes that are 
Classified as Cancer and Non-Cancer 
ENSEMBL annotated human genes were filtered for one-to-one orthologs and 
classified into genes that are associated with cancer (cancer) and the rest as ‘non-
cancer’. The percentage of translated amino acid sequence similarity of the genes 
for the groups is represented. X-axis represents the species – dog and human and 
the Y- axis shows the percentage of translated amino acid similarity between the two 
species. 
 
 
Figure 3.5 p-Value Distribution from Random Permutation of t-test 
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Genes from original dataset were randomly sampled 100 times and T-Test was 
performed between classes – cancer and non-cancer. The distribution of the p-Value 
is given in the histogram. X-axis has the p-Value and Y-axis shows the frequency.  
 
3.1.5 Summary 
From my preliminary analysis with ENSEMBL annotated gene conservation between dog 
and human we know that the genes associated with cancer are more conserved compared 
to the rest of the genes.  Few other notable comparative studies are published as of date, 
brief explanations of some of them are given. Poorman Et al (Poorman et al., 2015) 
compared aCGH expression data from malignant melanoma of human and canine 
samples and identified copy number aberration in CFA13, 17 and 22. Zhao’s(D. Liu et 
al., 2014) comparative study on WES and RNASeq mammary tumor revealed that 
complex carcinomas originate from epigenetic alteration. Another interesting work is the 
proof of principle study by Zhao with colorectal cancers in dog and human (Tang et al., 
2014). Her novel statistical approach was aimed at distinguishing drivers and passengers. 
They identified 73 driver cancer genes that were altered in both species and 38 passenger 
genes that were altered in human colorectal cancers. Thus it is clearly evident that 
comparative studies between dog and human have opened up new perspectives of the 
disease especially cancer.  
 
Importance of dogs as a model to study human diseases, especially cancer has been 
explained in previous chapters. However, often we do not know the role or function of a 
dog gene due to lack of functional annotation. Also, from my preliminary analysis, we 
know than the genes associated with cancer are more conserved than the others in terms 
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of sequence similarity. Additionally, identification of pathogenic mutations in human 
cancer based on genomic profiling has depended in part on determination of their pattern 
and frequency. Priority is given to genes that are frequently mutated in cancer and/or 
those mutations that have been shown through functional studies to play a role in 
oncogenic phenotypes.  However, when functional data is limited and/or when mutations 
occur at low frequencies, it remains challenging to determine the role of those mutations 
in cancer. Therefore, I have now developed an approach that holds potential for assisting 
in the prioritization of these genes and mutations and also better understand canine 
cancers. The workflow is based on a rigorous approach to evaluation of conservation 
metrics and co-occurrence of these mutations in human and canine cancer and will help 
to predict the tumor activity of an orthologous gene using multiple conservation metrics 
in DLBCL cancer. Canine samples were obtained from Elvers et al dataset deposited in 
SRA and human samples from TCGA. Based on function-oriented orthology annotation, 
we can infer that if a gene is conserved, its ortholog will have similar function and hence, 
when perturbed, will exhibit similar phenotype changes.  Using this principle, the genes 
are classified into one of the two classes – dog or human, based on the conservation 
scores like – sequence similarity, synteny, location in a pathway network using logistic 
regression. The probability of a gene being misclassified is high when it has similar bi-
directional conservation score. Such genes can have similar tumor activity in both 
species. Using this approach, we can not only begin to understand the dog cancers better 
but also understand the role of genes with low frequency mutation in human and identify 
novel drivers.  
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3.2. MATERIALS AND METHODS 
Data consists of raw FASTq files from canine DLBCL and MAFs from human. These 
were downloaded, processed through the pipeline and the genes with variants were 
shortlisted at first stage based on the criteria mentioned in the figure 3.6. These 
shortlisted genes were converted into standard nomenclature using HGNC and VGNC 
and then filtered again for one-2-one orthologs. Sequence similarity, synteny, whole 
genome alignment coverage, non- synonymous and synonymous nucleotide substitution 
rates, centrality of the gene in the protein-protein interaction network, per-gene mutation 
rate and average allele frequency were obtained for the filtered genes. Following the 
collection of data, genes were classified into 1) dog and human 2) concordant and 
discordant using logistic regression. Classification of concordant and discordant genes 
was tried with another model – random forest to get better accuracy. 
3.2.1 Data Download and Preprocessing 
3.2.1.1. Human Data Download and Processing 
The workflow starts by downloading the MAF files of 37 tumor normal matched WES 
DLBCL human samples from TCGA data portal. There are 4 MAF files – one for each 
caller, consisting of SNVs from– Somatic Snipper, MuSE, MuTect and VarScan.  Each 
of the callers identified 4,969, 6,094, 6,406 or 5,950 SNVs and INDELs in 4,878 genes.  
These were then imported into R and processed to extract the required variants and fields. 
As a first step, SNVs called by 3 or more callers were retained, followed by filtering for 
missense, frameshift, start or stop codon mutations resulting in 2,466 genes. Only genes 
and not specific SNVs were further considered in the analysis after this stage because the 
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aim of the approach is to identify orthologous genes with tumor activity and not the 
variations.  
 
 
Figure 3.6 Comparative Statistical Analysis Workflow 
The statistical workflow that is implemented to identify novel drivers is shown as a 
flowchart. T/N WES is the matched tumor normal samples that were Whole Exome 
Sequenced. Callers, filtering criteria at each stage and the final data list with the 
number of genes in each category is shown.  
 
3.2.1.2 Canine Data Download and Processing 
64 tumor normal matched WES B-Cell Lymphoma were downloaded from SRA website 
(https://www.ncbi.nlm.nih.gov/sra ) (Elvers et al., 2015) in the form of SRA files. These 
SRA files were converted to FASTQs using SRA toolkit and run through TGEN – 
HUMAN [HG] CANINE [CF] 
SNVs 
muTect, MuSe, Varscan, 
SomaticSniper 
SNVs 
muTect, Seurat, Strelka 
Filtering 
•  ! ENSEMBL IDs  
•  ! Paralogs 
•  ! synonyms 
Filtering 
Convert gene names to HGNC Convert gene names to VGNC 
Final list of genes 
 
HG : 2124  
CF : 333 
Intersect:106  
METRICS 
•  Mean AF 
•  Per-gene mutation & variance 
•  Centrality 
•  Betweenness 
•  Eigen vector 
•  Degree 
•  Trn Amino Acid sequence similarity 
•  Synteny 
•  Whole Genome Alignment 
Coverage 
•  dN, dS 
Logistic Regression Model 
37 T/N WES 
4878 genes 
64 T/N WES 
  5343 genes 
•  Missense, start, stop, 
InDels 
•  >=3 callers                
•  2466 genes 
•  Missense, start, stop, 
InDels  
•  >= 2 callers, ! contigs                
•   501 genes 
Filtering Filtering 
22 
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CERBERUS pipeline (described in chapter 2). 5343 genes were taken as input for first 
set of filtering and preprocessing in R. Similar to human, 2,066 genes with SNVs were 
called by 2 or more callers in known chromosomes (not in contigs). From this, only those 
genes that bore a missense, frameshift, start or stop codon variations were filtered 
resulting in 501 genes to be taken to the next steps.  
3.2.2. Converting Gene Nomenclature to HGNC And VGNC Format.  
To reconcile ambiguous gene names in order to avoid artifacts, I first converted all gene 
nomenclature resulting from the above gene list to standardized formats. HUGO Gene 
Nomenclature Committee (HGNC), which undertakes standardization of the human gene 
names, was expanded in 2016 and formed another committee called Vertebrate Gene 
Nomenclature Committee (VGNC). VGNC is a dedicated group responsible for assigning 
names to the vertebrates. Both groups work closely to ensure that orthologous genes are 
assigned equivalent names in the vertebrate species (Yates et al., 2017).  
 
Taking advantage of this recent development, all the filtered 2466 human genes bearing a 
SNV were explicitly converted to HGNC format using the HGNC tool (HGNC; Yates et 
al., 2017). Similarly, the 501 canine genes were also processed through the VGNC tool 
kit (VGNC). After the conversion, a second set of filtering was implemented to both the 
canine and human genes. To pass this stage, three criteria needed to be fulfilled and they 
are: 1) the genes should have an ENSEMBL ID, 2) they should be strictly one-to-one 
orthologs and 3) the mismatched gene names or genes with synonymous names for the 
existing gene in the list were eliminated. At the end of this step, 2,230 human genes and 
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439 canine genes were retained. Of these 106 genes were present in both the species. The 
final set of genes consists of 2,124 and 333 human and canine exclusive genes and 106 
intersecting genes (Figure 3.7).  
 
Figure 3.7 Representation of Number of Genes in Each Class 
The venn diagram shows the number of genes in class human and canine with 
intersection in the middle.  
 
3.2.3 Collection of Conservation Metrics 
For the above listed 2411 genes, different conservation scores were collected using 
multiple tools and consolidated into a single large matrix to generate a regression model. 
The main reason for using multiple metrics is to capture the conservation at various levels 
– sequence, sample and network level. These tools are described below. 
3.2.3.1 Mutation Burden 
For both gene classes, three sample level metrics were collected to run the logistic 
regression model. The per-gene mutation in each cohort was calculated separately and 
described as ‘count’. To account for noise, its variance was also included as another 
metric. This value shows the vulnerability of a gene to get a mutation with respect to 
others in the same set. The third is the average allele frequency of a gene in its respective 
HUMAN - 0 CANINE -1 
2124 333 106 
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class- human or dog. These metrics can be replaced with median or normalized mean to 
account for the actual variance and represent the sample cohort.     
3.2.3.2 Centralities : Protein- Protein Interaction Network 
The interplay of multiple genes can be visualized and studied using a network. Large and 
complex Protein-Protein Interaction (PPI) networks are investigated using centrality 
analysis. Centrality analysis is the ranking of the network elements to identify key players 
in the biological process (Koschützki & Schreiber, 2008). Each of these measures gives 
the importance of the gene in a network with respect to the rest. Centrality is calculated 
for every node in a directed or undirected graph. In a PPI interaction network, nodes are 
genes and the edges represent the interactions, usually undirected. Centrality measures 
assign a numerical value according to the importance/rank of a node and/or its 
connectivity in the network, thereby facilitating the measurement of the flow of 
information in a network. It helps to answer the questions – which gene is important and 
why. There are various ways to calculate the centrality of the node but it has been shown 
that a single value is not enough and multiple values are needed for a complex biological 
network analysis (Wuchty & Stadler, 2003).  Hence, I have used 3 measures here: 
betweenness, Eigen vector and degree centrality. Betweenness centrality assesses how 
often a node occurs on all shortest paths between any two nodes. This value measures the 
information flow and hence a node (gene) with high betweenness centrality can be a 
better target for drug candidates (Yu, Kim, Sprecher, Trifonov, & Gerstein, 2007).  On 
the other hand, degree centrality measures the number of neighbors a node has. 
Disturbing a node with a high degree centrality will affect the topology of the network 
59 
 
and hence can affect the functioning of the cell. Eigen vector centrality is similar to in-
degree centrality except for the fact that, weightage is given for only important nodes.  In 
other words the centrality index is calculated not only by using the position but also by 
the neighboring nodes. Hence using these 3 centrality indices we can rank the importance 
of a gene in the PPI network generated, for which STRINGDB plugin (Szklarczyk et al., 
2017) in Cytoscape was used. Two networks - one for each species, were constructed 
with all the genes that were obtained from the above filtering. CentiScaPe -plugin of 
Cytoscape (Scardoni, Petterlini, & Laudanna, 2009)  was used to calculate the centrality 
measures.  
3.2.3.3 Sequence Level Scores 
The comparative analysis pipeline of Biomart, called Compara (Herrero et al., 2016) was 
used to get the rest of the metrics viz; translated amino acid sequence similarity, synteny, 
whole genome alignment coverage, non-synonymous nucleotide substitution rate (dN) 
and synonymous nucleotide substitution rate (dS). Compara pipeline calculates the 
orthology by translating the nucleotide sequences to amino acid sequence. These 
sequences are run through NCBI blast+. MSA is performed on these protein clusters 
using M-COFFEE or MAFTT and then a phylogentic tree is built with TreeBeST using 
CDS back translation of the protein MSAs. Pairwise orthology and paralogy are inferred 
from this tree (ensembl, 2017).  
 
Sequence similarity was calculated using the translated amino acid sequence from the 
query to the target species. It has been shown that conserved syntenic genes are more 
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likely to have similar biological function(Overbeek, Fonstein, D’souza, Pusch, & 
Maltsev, 1999).  So it is assumed that if two genes are syntenic, then it’s ortholog is also 
likely to have high similarity and therefore similar function. Synteny is computed based 
on the arrangement of two genes above and beneath the gene of interest.  Region of 
interest is chained and netted to get the alignment coverage (Compara). dN and dS are the 
number of non-synonymous and synonymous substitution rate in gene of interest. These 
two values indicate the selective pressure acting on the protein-coding gene. A ratio of 
dN/dS greater than one indicates positive selection, less than one indicates purifying 
selection and equal to one indicates neutral selection.  All the eleven metrics were 
obtained for every gene and combined into a single matrix with rows as genes and 
columns as metrics. 
3.2.4 Regression Model 
Classification of genes was performed using logistic regression. Two classification 
models were generated 1) dog and human 2) concordant and discordance. Logistic 
regression (equation1.1) is used when one would want to estimate the probability of a 
particular value of the dependent value to occur, given the values of the independent 
variables. In both the cases, the dataset has 11 independent variables (evolutionary 
metrics) for every gene. Metrics for genes were calculated for the species it belongs to. 
Hence, 106 genes were represented twice (212). For the model 1 – genes that belong to 
dog were assigned to class 1 and human to class 0. In case of model 2, genes that were 
shared by both the dog and human (106 genes) were assigned to class 1 and those genes 
that were present in either of the species were assigned to class 0. For each model, every 
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class of data was separated into three groups to perform 3-fold cross validation with 2/3th 
as the training set and the rest 1/3th as the testing set.  
Equation 1 EXAMPLE LOGSITIC REGRESSION EQUATION 
LOGIT(DOG/HUMAN)= β0+ β1 (sequence similarity) + β2 (synteny) + β3 (WGAC) + β4 
(count) + β5 (variance) + β6 (AF) + β7 (Degree dentrality) + β8 (EV centrality) + β9 
(Betweenenss centrality) + β10 (dS) + βl1 (dN) + error 
 
3.3 RESULTS AND INTERPRETATION 
In order to identify genes in cDLBCL and hDLBCL that may be important drivers of 
these cancers, when mutated, but were previously not identified in this role, I 
implemented a novel comparative genomics workflow (Figure 3.3) utilizing curated SNV 
data derived from large-scale sequencing studies in both diseases. First, I downloaded the 
MAF files containing the SNV list for 37 tumor normal matched WES samples from 
TCGA and processed through R. FASTq files from 64 tumor normal WES samples were 
downloaded from SRA and processed through CERBERUS pipeline. The genes bearing 
coding variation were extracted and further filtered based on multiple conditions. 
Conservation metrics were obtained for the shortlisted genes. 3-fold cross validation 
logistic regression analysis was run to classify the genes into two classes – 1) dog and 
human and 2) concordant and discordant. Overview of hDLBCL and cDLBCL genomic 
landscape from the preliminary analysis is presented. It is known from previous studies 
that the cDLBCL did not carry any known hDLBCL driver mutations. My workflow 
helps to identify the novel drivers not only just based on the mutation frequency but also 
conservation of the gene between two species, thereby expressing similar function. By 
classifying the shortlisted genes that carry a SNV in both species into classes – dog and 
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human, 26 genes were mis-classified. These misclassified genes are of interest since they 
share similar conservation scores. Of these 26 genes, MUC17- associated with colorectal 
cancer was mis-classified bi-directionally. I also found other genes PCLO, BTG1, NME7, 
ELMO1, UBA1 that are known to play a role in DLBCL and other cancer types.  
3.3.1. cDLBCL is Characterized by Low Allele Frequency and Mutation Burden 
The hDLBCL cases had median mutation burden of 548 SNV and INDEL (range: 84-
2117). The median mutation burden of genes bearing somatic coding mutation is 78 
(range 1-302). Three samples (Figure 3.8b) had two fold more than median mutations, 
thus being outlier samples. cDLBCL samples had a median mutation burden of 37 
(range:4-317) somatic mutations that were called by two or more callers.  Though 11 
samples had two folds more than the median mutation rate (figure 3.8a), they were 
mostly non-coding mutations. Median and range of coding mutations in cDLBCL is 9.5 
and 1-56. Such a wide difference in mutation rate evidently leads to sample bias in the 
statistical analysis workflow. Missense variants dominated both species (Figure 3.9). 
Allele frequency in hDLBCL had a normal distribution with most of the variants falling 
in the range of 0.1-0.5 (Figure 3.10b). In cDLBCL, however, the allele frequency did not 
follow a normal distribution with most of the variants falling in the lower range – 
between 0.01-0.1 (Figure 3.10a). Lower allele frequency might be due to sub-clonal 
events or the samples might have lower tumor content. Hence in this case, species with 
similar cancer but different mutation burden are being compared. Recurrently mutated 
genes in cDLBCL are  FBXW7, MUC17 and TRAF3, whereas in hDLBCL are  PIM1, 
gene in immunoglobulin region (IGHG1,IGHG2, IGHV2, IGHM) and BTG2. The 
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observed difference in the landscape of the two species might be attributed to the fact that 
cDBCL is represented from only two breeds. It is known that there are inherent 
differences amongst the breed. With inclusion of more breed types, variation in the data 
could be reduced.   
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Figure 3.8 Distribution of Somatic Coding Variants Per Sample in a) cDLBCL b) 
hDLBCL 
Sample-wise distribution of somatic coding variants in canine and human DLBCL is 
represented. The sample IDs are mentioned in the X-axis and the frequency in the 
Y-axis. 
 
  
 
Figure 3.9 Frequency Distribution of Somatic Coding Variations  By Variant Type 
in A) cDLBCL AND b) hDLBCL 
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Frequency of somatic coding mutation variant types is distributed with variant type 
on the X-axis and frequency in Y-axis 
 
 
Figure 3.10 Allele Frequency Distirbution of The Somatic Coding Variation in A) 
cDLBCL AND b) hDLBCL 
Frequency of somatic coding mutation variant types is distributed with variant type 
on the X-axis and frequency in Y-axis 
 
 
3.3.2. CONSERVATION SCORES ARE SKEWED 
The final dataset consists of 2,473 genes  - 333 and 2,124 exclusively from dog and 
human and 106 genes that were present in both the species, with 11 conservation metrics. 
These conservation scores represent the independent variables of the regression model. 
The independent variables are plotted as a violin plot against human and canine to see the 
difference in the distribution of the values (figure 3.11). It is evident that except for allele 
frequency, none of the other metrics have a wide range of distribution. There are many 
outliers and most of the values fall in the lower range. Sample bias is represented by the 
thinner density curves. Also, we can observe that most of the genes have high sequence 
similarity and synteny. Betweenness centrality value was increase by a factor of 1 to 
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avoid infinities when plotted in log scale. Higher density at log value 1 shows that there 
are not many sub-clusters within the large PPI network.  
 
Figure 3.11 Violin Plots of The Conservation Metrics 
The X-axis represents the class with 0 indicating the human genes and 1 indicating 
the dog genes with the Y-axis denoting the frequency. Three lines inside every 
density graph denote the three quartiles.  
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3.3.3. Logistic Regression Model 
Results from the two logistic regression models are explained here. In model1, the genes 
were classified based on the species it belongs to (dog and human), whereas in model 2, 
the genes were classified based on the agreement (concordance and discordance).  
3.3.3.1 Model 1: Identification of Important Drivers Based on Function-Oriented 
Orthology in Dog and Human DLBCL 
The aim of this analysis is to identify the orthologous genes that could be associated with 
tumor activity, based on conservation metrics. Therefore, the genes that bore a somatic 
coding mutation in human or canine DLBCL and passed all the above-mentioned filtering 
criteria were separated into two classes – human and dog. Class 1 – representing dogs had 
439 events (genes) and class 0- representing humans had 2230 events.  3-fold cross-
validated logistic regression analysis with genes are events, class as dependent variable 
and 11 conservation score as independent variable was run where 2/3rd of the data from 
each class was used as training set and the rest 1/3rd as the test set. Once the model was 
generated, the fit was evaluated using deviance residual plots (Figure 3.12). Residuals 
reflect the difference between the fitted and the observed value. A perfectly fit model will 
have residuals plotted across the horizontal line in the residual Vs fitted graph.  From 
these plots, we can see that there are outliers (points 361,269 and 243) and one of the 
reasons for lack of perfect fit could be due to these outliers. Elimination of those points 
(genes) might help in an absolute classification. From the residual vs Leverage curve, we 
can see that there are two leverage points, points that deviates from the mean and can 
have unusually large effect on the model. For example, in figure 3.13, a scatterplot of, 
68 
 
leverage points are those with low similarity but high synteny. From this analysis, none 
of the outliers or the leverage points were removed.  
 
Figure 3.12 Logistic Regression Residual Plots with Dog and Human as Class 
The panel has quality control plots for the logistic regression with dog and human 
as class a) residual Vs Fitted, b) normal Q-Q plot b) scale-location, d) Residual Vs 
Leverage. 
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Figure 3.13 Scatterplot of amino acid similarity and synteny.  
The figure shows the correlation of the two conservation metrics, amino acid 
similarity and synteny. Top right extreme points are examples of leverages.  
 
Once the fit of the logistic regression model was assessed, performance of the 3-fold 
cross-validated model was evaluated with the tabulated accuracy metrics (Table 3.1) and 
the ROC curves (Figure 3.14). The classification was successful based on average 
accuracy of 99%, AUC of 0.9675 and F1 value of 0.99. The probability threshold to 
determine if an event should belong to class 1 (dog) was set to greater than 0.4. This 
threshold was set based on the ROC curve, the point with highest sensitivity and 
specificity. In order to identify the genes that have similar conservation between both 
species, the entire dataset was used to train and test the model. This final model has an 
accuracy of 98.9%, and AUC of 0.9667, with the same probability threshold to classify 
the genes to class 1 (dog). The confusion matrix, a kind of contingency table, showing the 
actual and the predicted values, is tabulated for the cross validation and the whole data 
model (Table 3.2). It is a 2X2 matrix used for visual representation of the error rate. The 
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genes that were classified to any of the species class were termed as ‘misclassified genes’ 
and were noted separately for further assessment (Table 3.3).  
 
Figure 3.14 Three Fold Cross Validation ROC Curve for Logistic Regression 
ROC curve for the logistic regression model for class human and dog with 3-fold 
cross validation is represented.  
 
Table 3.1 MODEL 1: Evaluation Metrics From 3-Fold Cross Validation & Whole 
Data 
METRICS CV-1 CV-2 CV-3 WHOLE DATA 
Sensitivity 1 0.9972 0.9986 0.9973 
Specificity 0.9512 0.9492 0.92 0.9472 
PPR 0.9917 0.9917 0.9863 0.9901 
NPR 1 0.9825 0.9914 0.9850 
Precision 0.9917 0.9917 0.9863 0.9901 
Recall 1 0.9972 0.9986 0.9973 
F1 0.9958 0.9945 0.9924 0.9937 
Prevalence 0.8529 0.8597 0.8522 0.8410 
Accuracy 0.9928 0.9905 0.987 0.9893 
AUC 0.9573 0.9824 0.9627 0.9667 
Metrics calculated from the 3-fold classification of the model with class dog and human 
as class. Genes that had a probability of greater than 0.4,were classified to class ‘dog’. 
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Table 3.2 MODEL 1: Confusion Matrix for The Whole Dataset 
PREDICTION\ACTUAL 0 1 
CROSS VALIDATION 1 
0 713 6 
1 0 117 
CROSS VALIDATION 2 
0 721 6 
1 2 112 
CROSS VALIDATION 3 
0 720 10 
1 1 115 
WHOLE DATA 
0 2202 22 
1 6 396 
Class 0 and 1 represent human and canine respectively. The model was evaluated with a 
prediction probability of 0.4 for positive class 0- human with entire dataset for training 
and testing. 
 
Table 3.3 List of Misclassified Genes 
PCLO TACC2 PPP6R1 SRGAP3 
KMT2D CKAP5 HAVCR1 BCORL1 
LRP1B DOCK1 IGHM LINS1 
BTG1 PNRC1 SAMD9L RPL23 
KLHL6 CCDC129 UBA1 ENSCAFG00000019472 
TENM3 NME7 DDX21 ENSCAFG00000023850 
MUC17 ELMO1 MPRIP   
3.3.3.2 cDLBCL Defining Novel Drivers in hDLBCL 
From table 3.2 (Whole data), we know that 28 genes are mis-classified of which MUC17 
was mis-classified bi-directionally, in other words conservation scores for the gene 
MUC17 with dog as query was predicted to belong to the class human and vice versa for 
the same gene with conservation scores from human. This shows a strong conservation 
similarity of MUC17 between dog and human.  Two of the mis-classified genes from the 
remaining pool, had only ENSEMBL gene ID with no protein function associated, 
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thereby reducing the list to 25 genes.  Misclassification of the genes might be either due 
to the biology of the genes (similar conservation) or technical shortcomings. Lack of 
experimental data for some of the conservation scores for dog and the like is termed as 
technical shortcoming here. In such cases, the tools mostly computationally extrapolate 
the human data to dogs, which can be partially explained by the table 3.2, where more 
genes (22) from class dogs are mis-classified compared to class human (6).   It is difficult 
to completely address this possibility without deeper gene annotation enabled by 
expanded phenotypic studies in dogs.  If, however, misclassification is driven by biology, 
then these 25 genes are interesting because they have similar conservation between the 
species and hence based on function-oriented gene orthology hypothesis, these genes can 
have similar tumor activity and phenotype when perturbed.  
 
The frequency with which these 25 genes are mutated in hDLBCL was assessed in 
cBioPortal. cBioPortal included an extended cohort of 58 hDLBCL samples from 
BROAD, along with the TCGA dataset that was used in this dataset. Investigation of 
these genes in a larger cohort will increase the confidence. PCLO, KMT2D, LRP1B, 
BTG1, KLHL6 are the only five genes from the list of 25 that were misclassified that are 
mutated (SNV or CNV) at greater than 10% frequency in hDLBCL (Figure 3.15). Genes 
with somatic coding SNVs, CNVs were included in comparing with hDLBCL from 
cBioPortal because, similarly conserved genes can have any type of aberration in 
DLBCL. Also, the pathogenicity status in cancer were noted from COSMIC ("COSMIC 
webpage," ; Simon A. Forbes et al., 2017), followed by specific tissue these genes are 
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expressed and pathway enrichment from DAVID (Huang da, Sherman, & Lempicki, 
2009a, 2009b).  
 
Figure 3.15 Oncoprint of Misclassified Genes in hDLBCL 
The samples from BROAD and TCGA are represented as grey box, percentage of 
frequency of alteration of the gene in entire cohort is given along the vertical axis. 
CNV, Missense and truncating mutations are shaded in the sample box.  
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A similar oncoprint for cDLBCL for the 25 misclassified genes is shown in figure 3.16. 
The percentages were calculated for 58 samples since only these bore a confident somatic 
coding SNV. A detailed table for all the 25 genes with conservation scores in both 
species and associated function and the tissue in which they are expression in human is 
given in Appendix II,III and IV 
 
 
Figure 3.16 Oncoprint of Misclassified Genes in cDLBCL 
Misclassified genes bore mutations in at least one of the 57 samples from 64 
cDLBCL patients that were used in this analysis. Samples are shown as grey box, 
genes in Y-axis with the percentage, green box represents missense mutation, red is 
frameshift mutation and black boxes are stop gained mutation.  
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Following inferences were made from this analysis: 
All of the genes are known to have a pathogenic mutation associated with cancer 
(appendix table 1). PCLO, BTG1 ,NME7, ELMO1, UBA1 are expressed in lymph and/or 
bone marrow. Though approximately 88% (out of 2669 genes) of the input genes have 
cancer association, segregation of these 25 – most of which are known to be involved in 
human lymphoma, shows that the misclassified genes might be associated with DLBCL 
in both the species due to conservation and a variation in these genes can lead to similar 
phenotype. For example, TENM3 is known to bear a mutation in human and we can see 
the same in dog as well.  PCLO, KMT2D, LRP1B, BTG1, MUC17, TACC2 are already 
published to be present in lymphoma. From my data, it is observed that DOCK1, 
KMT2D, MUC17, PCLO,TACC2 and TENM3 had somatic coding mutations in both 
human and dog patients at low sample frequency hinting that these six genes need more 
investigation with expression analysis.  The rest of the genes were mutated in either one 
of the species suggesting that they might still be important but the driving events behind 
them is yet to be found. This method is also helpful in identifying possible drivers – for 
instance PCLO, the most interesting gene, has five truncating mutations of unknown 
significance in human (figure3.11). It functions as a part of presynaptic cytoskeletal 
matrix. Work by Jens Lohr (Lohr et al., 2012) in hDLBCL identified that 35% of their 
sample set had mutations in this gene. Since, the dN/dS ratio was consistent with their 
dataset, many were considered as passengers. In depth investigation of this gene and its 
associated mutation can lead to new insights. Refer to appendix table 1 for more 
information about these genes. 
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MUC17 is also interesting because it was the only gene misclassified in both directions 
(human and dog). It has a low amino acid similarity – 20% and 18% in human and dog 
respectively, plays a role maintaining homeostasis of mucosal surfaces and somatic 
mutations in this gene are usually associated with carcinoma (Junker & Batra, 2008). 
There is a 100% synteny with 8/106 (8%) and 6/64 (9%) of the human and dog samples 
bearing somatic coding SNV/INDEL in this cohort. Due to the large gene size -38KB and 
breed specificity in the analyzed cohort, MUC17 could be a passenger gene. This analysis 
shows that MUC17, PCLO and others should be studied extensively more with respect to 
DLBCL in both species to gain better understanding of their role in dogs and humans.   
3.3.3.3. Model 2: Protein Sequence Similarity of Concordant Genes is Significantly 
Higher than Discordant Genes in DLBCL 
The previous model (model-1) was based on the assumption that the genes that did not 
fall into either dog or human class uniquely where those that shared a similar 
conservation. Model-1 is capable to identify both passenger and driver genes in one/both 
the species when the cancer type is not similar, like DLBCL. On the other, if the genes 
are classified into concordant or discordant (genes bearing a somatic coding mutation in 
both dogs and humans and those that are present in either dog or human), we can separate 
the group of genes that could potentially play a major role in tumor activity in both 
species from those involved in either of the species. This improved model could be used 
in the case of cancers that are proven to be similar in dogs and humans like melanoma.  
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Hence logistic regression model was created with concordance and discordance as class 1 
and 0 respectively with class 0 as the positive class. Class 1- concordance has 106 unique 
(figure 3.4) genes present in both the species bearing a somatic coding mutation. For 
these genes, the metrics are obtained from human and dog (bi-directional), resulting in 
212 events. Class 0 – discordance has 2457 events (figure 3.4). Welch’s T-Test was 
performed between the two classes of genes using translated amino acid similarity to 
estimate the difference in the sample mean. The sample estimates were 83.6270 and 
77.9196 respectively for the concordance and discordance respectively, with a p-value of 
5.616e-05, implying that the sequence similarity of the concordant genes is significantly 
greater than the discordant genes. Hence a robust classification should be able to group 
such similar conserved concordant genes together.  
Table 3.4 Model 2: Evaluation Metrics from 3-Fold Cross Validation  
METRICS CV1 CV2 CV3 
Sensitivity 0.8303 0.9011 0.8156 
Specificity 0.3286 0.2778 0.2714 
PPR 0.9354 0.9342 0.9291 
NPR 0.1420 0.1980 0.1118 
Precision 0.9354 0.9342 0.9291 
Recall 0.8303 0.9011 0.8156 
F1 0.8797 0.9173 0.8687 
Prevalence 0.9213 0.9192 0.9213 
Accuracy 0.8391 0.8305 0.7660 
AUC 0.6464 0.6213 0.5192 
The cross-validation models were generated after splitting the dataset into 3 fold -2 fold 
for training and the balance for testing. Prediction probability threshold of class 1- 
concordance is set to greater than 0.1 
 
To assess the variation of the dependent variable (class) as the independent variable 
changes, a logistic regression model was generated, with class 0 and 1 as the discordant 
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and concordant groups and the conservation scores as independent variables. The dataset 
has 212 (106 concordant genes for dog and human) rows and 11 conservation scores as 
the columns. 3 fold cross validation was performed by splitting the data into three groups 
from each group for each species. 2/3rd of this data was used as training set and 1/3rd as 
the test set. Probability threshold to predict class 1 was set as greater than 0.1 based on 
the ROC curve (figure 3.17). Model evaluation scores are tabulated (Table 3.4) for the 3 
iterations. The model performed fairly well with high sensitivity- 0.8490 and accuracy- 
0.8119. But it has a low specificity 0.2926 and AUC is only 0.5956, denoting that fine-
tuning is required. 
 
Table 3.5 Confusion Matrix for Model 2 
PREDICTION\ACTUAL 0 1 
CROSS VALIDATION 1 
0 725 49 
1 94 21 
CROSS VALIDATION 2 
0 719 51 
1 100 21 
CROSS VALIDATION 3 
0 660 49 
1 159 21 
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Figure 3.17 ROC Curve From Three-Fold Cross Validation Using Concordance and 
Discordance as Class 
ROC Curve for logistic regression model classifying the dataset into concordant and 
discordant group.  
 
Though model 2 performs well, it could be tuned to get more accurate classification by 
increasing the specificity. Hence other method like random forest classification technique 
is implemented. Accurate classification of concordant and discordant genes will not only 
help in identifying the drivers in both species but also quantitatively show that cDLBCL 
is a good model for hDLBCL based on evolutionary metrics.  
3.3.4 Advantages and Disadvantages of Classification of Genes Based on 
Conservation  
First and foremost, this statistical workflow is a novel attempt in trying to classify genes 
bearing somatic coding mutation in dog and human into classes of interest based on 
multiple evolutionary metrics. Based on function oriented orthology based gene 
annotation, genes with similar conservation should have similar function, hence that are 
classified as concordant class (model 2) should have similar tumor activity when 
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perturbed. Likewise, the genes that do not classify into either dog or human class 
uniquely should have similar conservation, thereby similar tumor activity (model1).   
With accurate classification, one should be able to identify important drivers in 
either/both dog and human cancer that was previously overlooked. Another advantage of 
this statistical workflow is it is not species or disease specific and hence can be easily 
extrapolated to study any two organism and any disease or non-disease condition – like 
hair color in a population. Also, this method will help to prioritize genes that have low 
mutation frequency in human cancers and/or their function not annotated, opening new 
doors for further laboratory experimentation.  
 
First problem to be addressed is the usage of biased dataset causing quasi separation. 
Also, it is known that this particular dataset and the cancer type that was used to generate 
the workflow have very low overlap with the human counterpart. The authors stated that 
the known drivers in human DLBCL were not seen in this set of canine samples (Elvers 
et al., 2015). Though, this is the only largest publicly available canine data, the breed 
specificity might only supplement the issue by reducing the diversity. Use of datasets 
from other cancer types like osteosarcoma or melanoma that are more representative of 
human cancer type will help in addressing the quasi separation and accurate classification 
of the genes.  
 
The second problem is the identification of a gene as an ortholog. It is an ongoing issue 
with continued active research to formulate the best way to classify the orthologs and 
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paralogs. Since this workflow depends on usage of true orthologs, precise identification 
of these groups of homologs is required to reduce false positive rate. Third issue is with 
metrics: independent variable or the conservation scores. Though stringent criteria were 
applied to extract experimentally verified PPIs, most of the values are lifted over from 
human, assuming that the genes are orthologs. This is a chicken and egg problem, where 
constant effort is going on to come up with the best approach for identifying orthologs 
using these metrics. Conversely, these networks and conservations scores are dependent 
on the identification of orthologous genes. Also, as mentioned in the earlier sections, 
experimental validations are usually performed in yeast, or mouse but not in dogs or cats. 
Additionally, logistic regression is only a linear transformation of the data points. These 
data points, especially model2 could be separated using higher order transformation like 
support vector machine.  Hence, there is a need to perform basic science experiments to 
know about these species better and thereby study its orthologs – human better too.  
3.4. CONCLUSION 
With a non-standard model organism like dog, it is almost impractical or impossible to 
estimate the conservation scores. Hence a theoretical approach has been taken to 
differentiate the genes involved in DLBCL, based on its presence or absence in the dog 
and human and thereby predict their tumor activity and prioritize genes with unknown 
function in human. Such an analysis is important to provide statistical evidence of gene 
conversation based on multiple metrics. We found that the classification of genes bearing 
somatic coding mutations in DLBCL based on its presence in dog or human, using 
logistic regression worked almost well. All 25 misclassified genes had a pathogenic 
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cancer mutation. MUC17 and PCLO are particularly interesting due to the reasons stated 
above. Thus, a novel classification methodology and interpretation of comparative 
genomics was implemented successfully, in case of using a not so similar cancer type, 
DLBCL. On the other hand, if the dataset used is from a cancer type that is proven to be 
similar – example melanoma, a classification based on concordance and discordance 
could be performed.   
 
Further, classification of genes based on species (model 1) will be improved by adding 
genes with CNVs and SVs. The results from this classification can be cross-verified with 
RNA data, when available. Eventually, such an improvement should help throw light 
about genes like BCOR1 that is present in dog only and not in human but was 
misclassified. Both the logistic regression models will be fine tuned to get better 
specificity by including interaction terms. In both the models, we see a sample bias, with 
one class being over dominated. Hence methods like Firth’s logistic regression, will be 
implemented to account for the bias.  Firth’s method uses penalization of the maximum 
likelihood scores thereby reducing the small sample bias and hence is better than 
downsampling the data. Disadvantage of losing data by over/under sampling and 
handling the quasi separation problem, major issues in the above two logistic regression 
models, can be addressed by Firth’s Logistic regression. 
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Chapter 4  
CONCLUSIONS AND FUTURE DIRECTIONS 
Genomic techniques are constantly improving and helping accelerate identification of the 
landscape of aberrations associated with complex diseases like cancer. Biomedical 
research is rapidly moving in the direction of increasing affordability and data quality 
while decreasing sequencing time. Because sequencing costs have already dropped below 
$1,000 per genome, a need exists for informatics methodologies to simultaneously 
improve. Integrating data from multiple platforms like genomic, transcriptomic, and 
epigenomic data, is a key and active area of research in the field of biomedical 
informatics. Systems biology integrates mathematics, physics and engineering with 
biological and clinical data to explain the rewiring and cellular behavior of a tumor cell 
and predict patient outcome. The cross-disciplinary integration of these approaches - 
systems biology, biomedical informatics and multiomics - will help in converting multi-
dimensional complex biological data into useable information including. Specific 
outcomes may include identification of useful clinical biomarkers, predicting the 
phenotypes of specific mutations, or predicting clinical trial outcomes based on molecular 
profiles. Such powerful approaches will in turn help to classify patients based on disease 
progression, will help guide study of new treatment modalities, and will facilitate 
assignment of optimal and customized treatment options. Given the wide spectrum of 
mutations in cancer and the importance of classification of tumors in cancer diagnosis 
and treatment, it is challenging to identify genes that are associated with a subtype or 
cancer type from the pool of thousands of genes. Hence statistical classification methods 
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such as those I have developed will be critically important for all of the above-mentioned 
efforts.  For example, new methods that identify and prioritize novel drug targets (such as 
previously unrecognized cancer drivers) can be of enormous benefit for cancer precision 
medicine.  
 
 Comparative oncology has now shown value not only for understanding biology across 
species,  but also for identification of novel drivers and passengers that could have been 
missed in the organism of interest via typical approaches based on mutation frequency 
and known functional effect. Due to the lack of robust pipelines and workflows for rarely 
utilized model organisms like cats and dogs, systematic analysis of genes and gene 
variants will take significant additional time and effort. Here, I have made a novel 
attempt to integrate systems biology, evolutionary conservation and genomic data to 
classify and predict the orthology of canine cancer genes with human cancer genes. 
Having built a robustcanine cancer genomics pipeline and a statistical workflow based on 
conservation metrics, I have now established a new method of identifying putative cancer 
genes that merit additional functional study. This analysis will serve as a starting point 
for further laboratory experiments and will also facilitate the exploration of the cross 
species analysis from a new perspective.   
 
FUTURE DIRECTIONS 
Significant remaining needs exist for improving the canine cancer genomics pipeline. 
First, I will seek to incorporate all variant calling approaches into one uniform pipeline 
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with a wrapper. For example, copy number, translocation, differential expression, fusion 
calling will be incorporated. To enable incorporation of differential expression and 
fusions calling, we will first test multiple tools as done for CNV and SV callers. Next, a 
significant need exist for expanded annotation of canine genes (both functional 
annotation and annotation of their roles in disease) and for development of effective 
annotation tools. SNPEff (P. Cingolani et al., 2012), commonly used for variant 
annotation in human cancers, does not perform well in canine gene variants. It does not 
annotate the position where amino acid change occurs precisely.  Thus, I will explore 
addition of other annotation tools such as Variant Effect predictor (McLaren et al., 2016) 
and ANNOVAR (K. Wang, Li, & Hakonarson, 2010) will be tried and added to the 
pipeline if effective.  
 
One of the major challenges in working with genomic data is the prediction of the 
functional impact of variations in both human and non-human species. Such annotation is 
more challenging and arduous when 1) the variations are in non-coding regions of the 
genome, 2) structural or functional information is not available, and 3) there is little direct 
knowledge of the role of a specific variant in pathway signaling and/or drug response. To 
address a few of these challenges, I will generate an improved regression model that 
incorporates all types of SNVs (missense, frameshift, UTR, Stop and start codon and in-
frame). I will additionally include genes impacted by CNVs, SVs, and potentially even 
with orthogonal significant expression changes. For instance, a homozygous deletion 
with simultaneous loss of expression will prioritize a gene for inclusion. I will also 
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evaluate other statistical models that may enable better classification of concordant and 
discordant genes such as support vector machines. Ultimately, as more canine cancer 
datasets become available in our laboratory and others, I will evaluate this approach in 
those data and will work to collaborate with bench scientists to test hypotheses about the 
oncogenic roles of genes that I identify. Finally, it would be interesting to assess whether 
this model might be useful in comparative assessment of other disease across species – 
whether cancers in multiple species or other complex multi-genic diseases in dogs and 
humans. 
 
Overall, this work has shown promise for opening new doors in the field of comparative 
oncology and genomics. It has also helped define canine cancer genome landscapes and 
has prioritized putative cancer genes for further study by system biologists and bench 
scientists.   
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APPENDIX I 
SOMATIC CNVS IDENTIFIED IN THE DISCOVERY COHORT OF CANINE 
MELANOMA 
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Genomic 
Coordinates 
Region 1 
Genomic 
Coordinates 
Region 2 
Rearrangement 
Type Gene(s) Affected 
10:3939331 10:10584581 Deletion SLC16A7-SNORA31 
10:41648330 10:58569528 Deletion SNORD89, RNF149 
10:48848646 10:55043815 Deletion CRIPT 
10:55134592 10:59905904 Deletion ACYP2 
14:8556800 14:13003884 Deletion SND1 
15:43643754 15:43655069 Deletion HHIP-ANAPC10 
16:36084348 16:36102394 Deletion ENSCAFG00000006745 
16:38429151 16:48085768 Deletion cfa-mir-383-TUSC3 
18:55715013 18:55715576 Deletion MAD2L1-NAA38 
20:17219966 20:17221394 Deletion ENSCAFG00000006312-PGK1 
21:2558450 21:19216762 Deletion 
ENSCAFG00000030067-
ENSCAFG00000013779 
37:2976116 37:19347267 Deletion 
ENSCAFG00000010125-
PCGEM1 
10:3939577 10:10589382 Duplication SLC16A7-SNORA31 
10:49028619 10:63492181 Duplication SOCS5-U6 
10:49816503 10:53208377 Duplication U4-MSH6 
10:55977973 10:60531942 Duplication ENSCAFG00000002811-U4 
14:4941520 14:6384069 Duplication PLXNA4 
16:35980545 16:41068224 Duplication 
ENSCAFG00000025394-
ENSCAFG00000006745 
16:46655783 16:56530123 Duplication STOX2-TRAPPC11 
10:3658316 10:3660438 Inversion SLC16A7-SNORA31 
10:10813410 10:10814241 Inversion RAP1B 
10:10816981 10:10817965 Inversion RAP1B 
10:41830619 10:58588338 Inversion RPL31, TBC1D8 
10:48769472 10:52633890 Inversion RHOQ 
10:52614873 10:63572545 Inversion ENSCAFG00000002716 
10:57109559 10:60522725 Inversion CCDC85A 
10:58599712 10:59939014 Inversion FANCL 
10:60490240 10:63501149 Inversion FANCL-BCL11A 
16:8833552 16:47072871 Inversion PARP12 
16:46924991 16:49442022 Inversion 
ENSCAFG00000031482-
SNORA70 
16:49434464 16:49443420 Inversion 7SK-SNORD22 
14:6441886 10:57118562 Translocation COPG2, cfa-mir-335 
14:6623322 10:51476318 Translocation CPA4 
14:49159979 13:56773685 Translocation DNAJB9-SNORD116 
16:22315921 10:34453938 Translocation 
CSGALNACT1-
ENSCAFG00000005342 
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16:36112108 10:12765711 Translocation 
ENSCAFG00000006745-
LONRF1 
Genomic 
Coordinates 
Region 1 
Genomic 
Coordinates 
Region 2 
Rearrangement 
Type Gene(s) Affected 
16:48730032 10:61037053 Translocation 7SK-SNORD22 
16:48791202 10:55097943 Translocation 7SK-SNORD22 
16:56528530 14:14818391 Translocation U1-ENSCAFG00000008648 
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APPENDIX II 
 CONSERVATION SCORES OF THE MISCLASSIFIED GENES FROM 
MODEL:1 
Class is represents the species the value was obtained from – human (HG) and canine 
(CF), # samples tested and # coding mutations gives the number of samples that were 
used to find the pathogenicity (COSMIC) and the number of coding mutations in those 
samples. Sample freq cBIOPORTAL gives the number of hDLBCL samples that has a 
variation in that gene (cBIOPORTAL).  Amino acid similarity is the translated amino 
acid similarity of that particular gene and count is the number of cDLBCL samples with a 
mutation in that gene.  
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APPENDIX III 
GENE FAMILY OF THE MISSCLASSIFIED GENES FROM MODEL:1 
 
  
122 
 
 
 
GENE HGNC GENE FAMILY 
BCORL1 Ankyrin repeat domain containing 
BTG1 BTG/Tob family 
CKAP5 TOG domain containing 
DDX21 DEAD-box helicases 
DOCK1 Armadillo-like helical &DOCK C2 domain containing 
ELMO1 Engulment and cell motility proteins 
HAVCR1 CD molecules, V-set domain containing 
IGHM Immunoglobin heavy locus 
KLHL6 BTB domain containing, Kelch like 
KMT2D PHD finger proteins, SET domain containing, Lysine Methyltransferases, 
Trinucleotide repeat containing  
LRP1B Low density lipoprotein receptors 
MPRIP pleckstrin homology domain containing 
MUC17 mucins 
NME7 Cilia and flagella associated,NME/NM23 family  
PCLO Zinc finger,CD2,PDZ domain containing 
PPP6R1 Protein Phosphatases 6 regulatory subunits 
RPL23 L ribosomal proteins 
SAMD9L Sterile alpha motif domain containing 
SRGAP3 Rho GTPase activating proteins,F-BAR domain containing 
UBA1 Cilia and flagella associated,ubiquitin like modifier activating enzymes 
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APPENDIX IV 
TISSUES IN WHICH MISCLASSIFIED GENES FROM MODEL:1 ARE EXPRESSED 
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GENE EXPRESSION IN TISSUES 
BCORL1 Amygdala, Lymph, Spleen, Whole embryo, 
BTG1 Colon, Lymphoblastoma, Skin, Stomach, 
CCDC129 Cervix adenocarcinoma, Cervix carcinoma, Colon, Epithelium, Muscle, 
Pooled, Uterine endothelium, 
CKAP5 Brain, Lung cancer, 
DDX21 Alzheimer cortex, Brain, Urinary bladder, 
DOCK1 Brain, Platelet, Testis, 
ELMO1 Pooled, Testis, 
IGHM Epithelium, Placenta, 
KLHL6 Brain, Lung, Pancreas, Placenta, Testis, 
KMT2D Kidney, Liver, 
LINS1 Dermoid tumor, Esophagus tumor, Glandular pool- thyroid, Liver, 
Neuroblastoma, Placenta, Plasma, Primary B-Cells, Rectum tumor, Spleen, 
LRP1B Blood, Spleen, 
MUC17 Brain, Cervix carcinoma, Epithelium, 
NME7 Pancreatic adenocarcinoma, Small intestine, 
PCLO Aorta, Brain, Epithelium, Lymph, Melanoma, Muscle, Ovary, Tongue, 
PNRC1 Brain, Liver, PCR rescued clones, Placenta, Skin, Testis, 
RPL23 Brain, Lymph, Placenta, Skin, Testis, 
SRGAP3 Amygdala, Brain, Epithelium, Skin, Spleen, Uterus, 
TACC2 Brain, 
TENM3 Brain, Endothelial cell, Epithelium, Fetal brain, Placenta, Skeletal muscle, 
Testis, 
UBA1 Brain, Cajal-Retzius cell, Epithelium, Lymph, Placenta, 
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APPENDIX V 
SOMATIC INACTIVATING PTPRJ MUTATIONS AND DYSREGULATED 
PATHWAYS IDENTIFIED IN CANINE MELANOMA BY INTEGRATED 
COMPARATIVE GENOMIC ANALYSIS 
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ABSTRACT 
Canine malignant melanoma, a significant cause of mortality in domestic dogs, is 
a powerful comparative model for human melanoma, but little is known about its genetic 
etiology. We mapped the genomic landscape of canine melanoma through multi-platform 
analysis of 37 tumors (31 mucosal, 3 acral, 2 cutaneous, and 1 uveal) and 17 matching 
constitutional samples including long- and short-insert whole genome sequencing, RNA 
sequencing, array comparative genomic hybridization, single nucleotide polymorphism 
array, and targeted Sanger sequencing analyses.  We identified novel predominantly 
truncating mutations in the putative tumor suppressor gene PTPRJ in 19% of cases. No 
BRAF mutations were detected, but activating RAS mutations (24% of cases) occurred in 
conserved hotspots in all cutaneous and acral and 13% of mucosal subtypes. MDM2 
amplifications (24%) and TP53 mutations (19%) were mutually exclusive. Additional 
low-frequency recurrent alterations were observed amidst low point mutation rates, an 
absence of ultraviolet light mutational signatures, and an abundance of copy number and 
structural alterations. Mutations that modulate cell proliferation and cell cycle control 
were common and highlight therapeutic axes such as MEK and MDM2 inhibition. This 
mutational landscape resembles that seen in BRAF wild-type and sun-shielded human 
melanoma subtypes. Overall, these data inform biological comparisons between canine 
and human melanoma while suggesting actionable targets in both species. 
 
AUTHOR SUMMARY 
Melanoma, an aggressive cancer arising from transformed melanocytes, 
commonly occurs in pet dogs. Unlike human melanoma, which most often occurs in sun-
exposed cutaneous skin, canine melanoma typically arises in sun-shielded oral mucosa. 
Clinical features of canine melanoma resemble those of human melanoma, particularly 
the less common sun-shielded human subtypes. However, whereas the genomic basis of 
diverse human melanoma subtypes is well understood, canine melanoma genomics 
remain poorly defined. Similarly, although diverse new treatments for human melanoma 
based on a biologic disease understanding have recently shown dramatic improvements 
in outcomes for these patients, treatments for canine melanoma are limited and outcomes 
remain universally poor. Detailing the genomic basis of canine melanoma thus provides 
untapped potential for improving the lives of pet dogs while also helping to establish 
canine melanoma as a comparative model system for informing human melanoma 
biology and treatment. In order to better define the genomic landscape of canine 
melanoma, we performed multi-platform characterization of 37 tumors. Our integrated 
analysis confirms that these tumors commonly contain mutations in canine orthologs of 
human cancer genes such as RAS, MDM2, and TP53 as well mutational patterns that 
share important similarities with human melanoma subtypes. We have also found a new 
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putative cancer gene, PTPRJ, frequently mutated in canine melanoma. These data will 
guide additional biologic and therapeutic studies in canine melanoma while framing the 
utility of comparative studies of canine and human cancers more broadly. 
 
INTRODUCTION 
Human melanoma is of increasing clinical concern. It is one of a few cancers with 
rising incidence, while five-year survival for patients with metastatic disease has until 
recently remained low (15-20%) due to a dearth of curative systemic therapies(Siegel, 
Ma, Zou, & Jemal, 2014). Discovery of frequent activating BRAF mutations in 
melanoma and treatment with selective inhibitors of this mutant kinase has led to 
dramatic responses in the setting of metastatic disease(P. B. Chapman et al., 2011; Davies 
et al., 2002; Pollock et al., 2002)_ENREF_2_ENREF_4. However, not all BRAF-mutant 
melanomas respond to targeted therapy and responses that do occur are often brief and 
followed by the emergence of drug-resistant disease(Sun et al., 2014). Moreover, targeted 
treatment options in melanoma subtypes without activating BRAF mutations are limited. 
New treatment paradigms such as immunotherapy, drug combinations, and alternative 
dosing strategies may circumvent resistance and broaden the scope of precision medicine 
in melanoma(Flaherty, Infante, et al., 2012; Flaherty, Robert, et al., 2012; Hodi et al., 
2010; Thakur et al., 2013),_ENREF_6 but rapid preclinical study of such regimens 
requires access to robust models that recapitulate complex tumor features such as 
intratumoral genomic heterogeneity and tumor-host interactions. Meanwhile, few animal 
models exist for uncommon molecular or histological melanoma subtypes such as BRAF 
wild-type (BRAFwt) or mucosal melanoma. 
Naturally-occurring canine cancers are increasingly recognized as meeting a need 
for complex cancer models that develop gradually amidst interactions with host stroma 
and immune system(Bushell et al., 2015; Khanna et al., 2014; LeBlanc et al., 2016; D. 
Liu et al., 2014; Paoloni & Khanna, 2008; Schiffman & Breen, 2015; Tang et al., 2014). 
Spontaneous canine malignant melanomas, which are almost universally BRAFwt and for 
which the mucosal subtype is the most prevalent clinically significant form, may fill a 
specific gap in models of BRAFwt and rare histological melanoma subtypes(Paoloni & 
Khanna, 2008). Human mucosal melanoma is an aggressive histological subtype that is 
predominantly BRAF, RAS, and NF1 wild type (Triple Wild Type or TWT) with 
occasional mutations in KIT or NRAS and carries a five-year survival rate between 12.3% 
and 35.3% _ENREF_20_ENREF_16(Curtin et al., 2006; Curtin et al., 2005; Simon J 
Furney et al., 2013; Hayward et al., 2017; Krauthammer et al., 2012; Maldonado et al., 
2003; Manolidis & Donald, 1997; Meleti et al., 2008; Tanaka, Yamada, Tanaka, Shimizu, 
& Oka, 2004; Turajlic, Furney, Lambros, Mitsopoulos, Kozarewa, Geyer, MacKay, 
Hakas, Zvelebil, Lord, et al., 2012)_ENREF_13_ENREF_4_ENREF_9. Study of this 
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subtype is limited by its low prevalence, only 1-2% of human melanomas in the United 
States, with as few as 1,500 cases per year(Chang et al., 1998). On the other hand, canine 
malignant melanoma accounts for up to 100,000 yearly cancer diagnoses in the United 
States, occurring most commonly in the oral mucosa, but also arising in cutaneous and 
acral epithelium(Philip J. Bergman, 2007; Cotchin, 1955; S. H. Smith, M. H. 
Goldschmidt, & P. M. McManus, 2002; Villamil et al., 2011).  
Canine malignant melanoma is highly prevalent, closely mirrors human 
melanoma clinically and pathologically, and is extremely aggressive, with median 
survival for oral cases being a mere 200 days(P. Bergman, Kent, & Farese, 2013; Philip J 
Bergman & Wolchok, 2008; Gillard et al., 2014; Prasad et al., 2004; R Mark Simpson et 
al., 2014)_ENREF_20_ENREF_20_ENREF_20. However, little is known about its 
genetic etiology. It is predominantly BRAFwt with frequent copy number alterations of 
regions of canine chromosomes (CFA) 13, 17, 22, and 30, alongside frequent MYC 
amplifications and deletions of CDKN2A. Targeted sequencing studies, though limited, 
have shown that it infrequently bears alterations in other known drivers of human 
melanoma(Chu et al., 2013; J. S. Fowles, Denton, & Gustafson, 2013; Gillard et al., 
2014; Murakami et al., 2011; Poorman et al., 2014; Shelly et al., 2005; R Mark Simpson 
et al., 2014; Kathleen Spring, Lapointe, Caron, Langlois, & Royal, 2014). It has been 
shown that CFA 30 aberrations are characteristic of canine oral melanoma and complex 
copy number profiles on this chromosome homologous to the same profiles on human 
chromosome (HSA) 15 in human mucosal melanoma are suggestive of rearrangements 
that may drive this melanoma subtype (Poorman et al., 2014). Despite the very low 
prevalence of BRAF mutations, immunohistochemistry (IHC) has shown that the 
mitogen-activated protein kinase (MAPK) and/or phosphoinositide 3-kinase (PI3K) 
pathways are activated in 52-77% of cases(Chu et al., 2013; J. S. Fowles et al., 2013; 
Gillard et al., 2014; Murakami et al., 2011; Shelly et al., 2005; R Mark Simpson et al., 
2014). These data hint at underlying mutations driving these pathways that could guide 
future biological exploration and therapeutic development in the canine and human 
diseases.  
We therefore set out to map the genomic landscape of canine melanoma using a 
combination of massively parallel whole genome sequencing (WGS), array-based 
platforms and targeted sequencing to identify somatic changes driving these cancers. 
Here we report the identification of recurrent inactivating mutations in the candidate 
tumor suppressor gene PTPRJ in addition to frequent RAS mutations, and mutually-
exclusive MDM2 and TP53 alterations. We thereby define the genomic landscape of 
these cancers and identify similarities between melanoma subtypes across species while 
highlighting subtype-specific aberrations that may be used to guide future research. 
 
129 
 
RESULTS 
Patterns of mutation identified by whole genome analysis of canine melanoma. We 
undertook comprehensive analysis of acquired genetic alterations in a discovery cohort of 
seven melanomas and matched germlines from six dogs (two tumors were derived from 
one dog) using WGS for detection of subtle sequence alterations alongside long-insert 
WGS (LI-WGS, see Materials and Methods)(Winnie S Liang et al., 2014) for sensitive 
detection of structural variants. We then performed copy number and targeted gene 
analyses in an additional 27 tumors and three melanoma cell lines (Table 1). Tumors (all 
primary tumors except one acral metastasis) and matching whole blood were collected 
through the Van Andel Research Institute from dogs undergoing surgery at specialty 
veterinary clinics and immediately snap frozen. Diagnosis of melanoma was confirmed 
by two independent board certified veterinary pathologists in addition to staining for 
three melanocytic differentiation markers where tissue was available(R Mark Simpson et 
al., 2014; Smedley, Lamoureux, Sledge, & Kiupel, 2011)_ENREF_29_ENREF_29. 
Diverse breeds are represented in this cohort with enrichment for Cocker Spaniels and 
Golden Retrievers (five dogs of each breed), an equal ratio of male and female dogs and a 
median age at resection of 11 years. Clinicopathologic characteristics for this cohort are 
described in Supplementary Table 1 and Supplementary Figure 1.  
For WGS and LI-WGS respectively a median of 38/11-fold sequence coverage 
and 209/155-fold physical coverage was achieved (Supplementary Table 2). Read 
alignment was performed using the canine reference genome CanFam 3.1 and stringent 
criteria were used to call somatic sequence variants intersecting Seurat, Strelka and 
Mutect (Materials and Methods). A total of 31,053 somatic single nucleotide variants 
(SNVs) and small insertions and deletions (indels) were found with a median of 4,223 
genome-wide SNVs (range 1,880-6,342) and 316 indels (range 88 - 655) and a median 
mutation rate of 2.03 mutations per callable haploid megabase (range 0.97-3.14, Table 
2). The genome-wide SNV spectrum showed C:G>T:A transitions to be most prevalent, 
at a median of 27.09% of total SNVs followed by T:A>C:G transitions (median of 
21.19%) and C:G>A:T transversions (median 15.74% , Supplementary Figure 2A). 
Despite the prevalence of C:G>T:A transitions, most occurred in CpG dinucleotides and 
were not enriched at dipyrimidines (median 22.5%). Therefore, a canonical UV signature 
was not present in any of these cases (Supplementary Figure 2B)(Alexandrov et al., 
2013; Berger et al., 2012)_ENREF_27. We additionally looked for TERT promoter 
mutations, which have been reported in 71% of human cutaneous melanomas and are 
associated with UV damage(Huang et al., 2013), but no mutations were found within one 
kilobase of the TERT transcription start site. While no single mutation was represented at 
greater than 4% of the SNV population, C:G>T:A in GCG trinucleotides was the most 
common mutation (median 6.7%) followed by C>T in ACG (median 2.6%) and C>A in 
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TCT (median 2.5%) (Supplementary Figure 2C). No evidence of localized 
hypermutation (kataegis) was identified in these tumors(Nik-Zainal et al., 2012).  
 
Somatic coding mutations identified in canine melanoma. Tumors assessed by whole-
genome analysis displayed an abundance of somatic SVs and copy number variants 
(CNVs), with a modest burden of SNVs in coding regions (Figure 1A and 1B). The 
landscape of somatic mutations in the full cohort of 37 tumors based on multi-platform 
analysis is shown in Figure 1C. Circos plots depicting somatic alterations in each tumor 
in the discovery cohort are shown in Supplementary Figure 3. Of the genome-wide 
SNVs described above, a median of 26 nonsynonymous single-base substitutions and 
indels occurred within coding regions (nsSNVs, range 14-42) with a median 
nonsynonymous: synonymous mutation ratio of 2.3 (range 1.9-3.9) (Figure 1B). We 
additionally performed RNA sequencing in this cohort, aligning with TopHat and 
utilizing IGV to manually validate expressed sequence variants (Materials and Methods). 
Eighty-five percent of nsSNVs (all but 28) identified by WGS were confirmed by their 
presence in two or more sequencing platforms (Supplementary Table 3).  
A number of mutations in orthologs of human cancer genes were present in a 
single tumor each and include: ATF6, EPAS1, FAT2, FAT4, FOXA3, FOXO1, GAB2, 
HRAS, KIT, KRAS, MMP21, NRAS, PBX1, and XPO1. Although no recurrent SNVs were 
seen in the discovery cohort, three genes were mutated in two cases: FAT4, LRFN2, and 
PTPRJ. Of these, only PTRPJ was validated in multiple platforms in both cases. Both 
cases containing somatic PTPRJ mutations were mucosal (ND10-166 and ND10-376) 
and both putatively contained two hits. To determine the prevalence of mutations in a 
panel of genes whose orthologs are known to play a role in human melanomagenesis, as 
well as the PTPRJ gene mutated in two cases, we performed targeted Sanger sequencing 
of all protein-coding regions of BAP1, BRAF, CDK4, GNA11, GNAQ, KIT, KRAS, 
MDM2, MITF, NF1, NRAS, PTEN, PTPRJ, and TP53 in the expanded cohort. BRAF, 
CDK4, GNAQ, MDM2, MITF, and NF1 were all found to be universally wild-type 
whereas putative pathogenic mutations were discovered in BAP1, GNA11, KIT, KRAS, 
NRAS, PTEN, PTPRJ, and TP53 as described below and in Supplementary Table 4.  
 
Somatic copy number and structural variants identified in canine melanoma. 
Somatic CNVs in the discovery cohort were identified by analysis of short-insert whole 
genome sequencing (SI-WGS) using established methods (Materials and Methods). A 
median of 27 focal CNVs (range 4-68), two focal amplifications with a log2 ratio ≥ 2 
(range 0-61), and eight focal deletions with a log2 ratio ≤ 0.2 (range 3-41) were identified 
in the discovery cohort (Table 2 and Supplementary Table 5) comprising 0%-10% of 
the genome (Table 2). CNVs were additionally identified in this cohort utilizing Illumina 
131 
 
CanineHD BeadChip Single Nucleotide Polymorphism (SNP) arrays and Agilent 
SurePrint G3 Canine Genome CGH microarrays as previously described(Poorman et al., 
2014; M. Stark & Hayward, 2007) (Materials and Methods) with a high platform 
concordance (Supplementary Figure 4). CNV analysis was then expanded to a total of 
37 melanomas through SNP arrays in an additional 30 cases in the prevalence cohort 
(Table 1 and Supplementary Table 5). Altered regions were assessed by 
GISTIC(Mermel et al., 2011) for statistically significant frequency and amplitude (G-
score >1.0 and Q<0.05). Ten significant regions were identified including losses within 
CFA 1, 11, 15, and X, as well as gains in CFA10, 11, 13, 30, and X (Supplementary 
Table 6). Nine of 10 GISTIC regions contained genes and included gains in orthologs of 
the human cancer genes MDM2 and CDK4. Additional cancer driver alterations 
(homozygous deletions of tumor suppressor genes or focal amplifications of oncogenes) 
included CDKN2A homozygous deletion (3%) and KIT focal amplification (8%) 
(Supplementary Table 7). 
Somatic SVs including translocations, inversions, and duplications, were 
identified in the discovery cohort, based on calls from Delly(Rausch, Zichner, et al., 
2012) in LI-WGS (Materials and Methods). Between 9 and 65 predicted SVs were 
identified in each tumor (median 34) and were predominantly inversions (Table 2 and 
Supplementary Table 8). No recurrent rearrangements were present. Notable alterations 
in human cancer gene orthologs impacted by SVs in single cases include an ARHGEF12 
inversion, a BIRC3 inversion, a CLPTM1L-TERT translocation, a DDIT3 inversion, a 
MYO5A translocation, and a TCF12 inversion. However, two regions of CFA10 and 30 
were found to contain somatic SVs in two or more tumors. CFA10 rearrangements 
occurred in five of seven cases, four of which bore alterations in the region spanning 10 – 
12 Mb (also a significant GISTIC region from CNV analysis). CFA30 SVs were also 
present in three tumors with alterations occurring within a region spanning 15-24 Mb 
(also encompassing a GISTIC region) in each case. Complex chromosomal 
rearrangements reminiscent of chromothripsis were observed in four tumors (ND09-345, 
ND10-370, ND10-361, and ND10-441), with chained or clustered breakpoints localized 
to a subset of chromosomes in regions that also contained copy-number 
oscillations(Stephens et al., 2011) (Supplementary Figure 3). Gene fusions were also 
identified in RNAseq data using the TopHat-Fusion software package(Daehwan Kim & 
Steven L Salzberg, 2011) and IGV verification (Materials and Methods and 
Supplementary Table 8). Three fusions were identified in two tumors (OSBPL11-
NFKB1 and DGKA-ABCC5 in ND09-345, and RPTOR-TIMP2 in ND10-376) for which 
translocations were validated in LI-WGS on IGV inspection. No BRAF fusions were 
identified.  
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BRAF, RAS, NF1, and KIT mutations. Approximately 90% of human cutaneous 
melanomas are driven in part by BRAF, RAS, NF1, and KIT mutations that confer 
constitutive mitogenic signaling through the MAPK pathway(Berger et al., 2012; Hodis 
et al., 2012; Krauthammer et al., 2012). However, these alterations are far less common 
in human mucosal and acral melanomas(Curtin et al., 2006; Curtin et al., 2005; Simon J. 
Furney et al., 2013; Furney et al., 2014; Liang et al., 2017; Turajlic, Furney, Lambros, 
Mitsopoulos, Kozarewa, Geyer, MacKay, Hakas, Zvelebil, Lord, et al., 2012). No 
somatic alterations in BRAF were identified within any platform in our canine melanoma 
cohort. However, RAS family members, whose protein products are predicted to share 
100% sequence identity with their human orthologs, were the most commonly mutated 
genes in aggregate, occurring in 24% of cases in human-conserved hotspots (Figure 1C 
and 2A). NRAS codon 61 (Q61R/H/K) and KRAS codon 12 (G12C) mutations occurred 
each in four cases while a single case bore an HRAS Q61R mutation (nine total RAS 
mutations). All three acral and two cutaneous cases bore NRAS or KRAS mutations, while 
only 4/31 (13%) of mucosal cases bore an NRAS, KRAS, or HRAS mutation. Although 
NF1 copy number losses occurred in six cases, no homozygous deletions or truncating 
mutations were identified (Supplementary Table 7). KIT mutations were present in one 
cutaneous and two mucosal tumors (Supplementary Tables 3 and 4). In the cutaneous 
case, the mutation results in a glutamine (Q) to arginine (R) change in codon 396, notably 
a site of variation between canine and human orthologs, a change that is not predicted to 
be damaging by PROVEAN, and may constitute a germline SNP, but germline DNA was 
not available in this case(Choi, Sims, Murphy, Miller, & Chan, 2012). KIT mutations in 
the mucosal cases included an in-frame deletion of amino acids 560-562, a likely 
damaging mutation in a commonly mutated region of the human ortholog, as well as an 
aspartic acid (D) to valine (V) change in codon 815 corresponding to the most common 
hotspot D816V mutations occurring in the kinase domain of KIT in human cancers 
(Supplementary Figure 5)(Simon A Forbes et al., 2015). Copy number gains 
encompassing KIT were also present in 10 samples (eight mucosal, one acral, and one 
cutaneous – Jones, 17CM98, ND10-104, ND10-158, ND10-365, ND10-370, ND10-376, 
ND10-361, ND10-363, and ND10-441), although no focal amplifications were identified 
(Supplementary Table 7). 
 
PTPRJ Mutations. The most commonly mutated gene in this cohort was the putative 
tumor suppressor gene PTPRJ, not previously shown to have frequent inactivating point 
mutations in cancer (Figure 1C and 2C). PTPRJ (also known as density-enhanced 
phosphatase 1 (DEP-1) or CD148) is a protein tyrosine phosphatase receptor originally 
discovered by virtue of its overexpression in dense cultures of human lung 
fibroblasts(Ostman, Yang, & Tonks, 1994). It has since been shown to be frequently 
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involved in allelic loss or loss of heterozygosity (LOH) in human cancers and mouse 
models(C. Ruivenkamp et al., 2003; C. A. Ruivenkamp et al., 2002)_ENREF_51 and to 
potentially play a role in oncogenesis in diverse cancer types, but somatic homozygous 
deletions or truncating mutations have yet to be described in cancer from any species and 
its tumor suppressor status remains controversial(Gaudio et al., 2008; Godfrey et al., 
2012; Iuliano et al., 2004; Iuliano et al., 2010; Lesueur et al., 2005; Mita et al., 2010; 
Petermann et al., 2011; Toland, Rozek, Presswala, Rennert, & Gruber, 2008; Trapasso et 
al., 2006). Canine and human orthologs share 70% sequence identity with a highly 
conserved C terminus containing the protein tyrosine phosphatase catalytic domain that is 
nearly 100% identical between species (Supplementary Figure 6). Sequencing of 
PTPRJ across all 37 tumors revealed nine mutations in seven cases (all mucosal), 
comprising 19% of all tumors and 23% of mucosal cases. Six frameshifts or stop gains 
were discovered in addition to two splice site mutations, a C-terminal 10-amino acid 
deletion, and a single predicted damaging missense mutation. Two cases – ND10-190 and 
ND10-376 – contained two mutations each, consistent with putative bi-allelic inactivation 
of a tumor suppressor gene. Further, LOH was evident by analysis of adjacent SNPs in 
WGS data in case ND10-166 bearing the M110fs mutation (Supplementary Table 10). 
Consistent with this finding, the PTPRJ frameshift in the ND10-166 tumor occurred at an 
allele ratio of 61% in DNA and 100% in RNA. 
 
MDM2 Amplifications and TP53 Mutations. Inactivation of the p53 network is a 
critical step in tumorigenesis in nearly all cancers(Vogelstein, Lane, & Levine, 2000). 
Both truncating TP53 mutations and amplifications of MDM2, a negative regulator of 
p53, are key routes to p53 inactivation(Momand, Zambetti, Olson, George, & Levine, 
1992). Although TP53 mutations and MDM2 amplifications in human melanoma less 
common(Berger et al., 2012; Simon J Furney et al., 2013; Furney et al., 2014; Hodis et 
al., 2012; Krauthammer et al., 2012; Turajlic, Furney, Lambros, Mitsopoulos, Kozarewa, 
Geyer, MacKay, Hakas, Zvelebil, Lord, et al., 2012), 16/37 (43%) of the cases in our 
cohort of canine melanoma bore focal amplifications of MDM2 or truncating TP53 
mutations (Figure 1C). A recurrent focal amplification on CFA10 was identified by 
whole genome analysis in three of seven tumors in the discovery cohort with extended 
SNP array analysis in the prevalence cohort revealing an additional eight tumors bearing 
these amplifications (minimal region 10.9-11.8 Mb) (Figure 1C and 2C). In total, 11/38 
cases (29%) bore this amplification involving seven genes, with MDM2 being the likely 
amplification target (Figure 2B). All such amplifications occurred in mucosal 
melanomas (11/31, 35%). CDK4, a cancer gene 10 Mb proximal to MDM2 in both 
human and canine genomes and often the target of bipartite amplification alongside 
MDM2(Reifenberger et al., 1996; Wikman et al., 2005), was co-amplified in three of 
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these cases. Twenty tumors were additionally assessed for MDM2 expression by IHC 
(Supplementary Table 11 and Supplementary Figure 7). Three of five cases with 
MDM2 focal amplifications also showed prominent MDM2 staining while no cases 
lacking MDM2 amplifications were positive by IHC. 
We additionally discovered seven tumors with mutations in TP53 whose protein 
product shares 80% identity with its human ortholog (Supplementary Figure 8). Three 
of these mutations were truncating – a homozygous T90X in ND10-252, heterozygous 
K151fs in ND11-201, and a heterozygous Q306X in ND10-564 (Figure 2D and 
Supplementary Table 4). Of the three missense mutations, R145C and R270H were 
predicted to be damaging. R145C occurred in two tumors and R270H in a single tumor, 
with both mutations confirmed somatic through analysis of matched germline DNA. 
Codon 270 in canine TP53 is homologous to codon 282 in human TP53, the fifth most 
common hotspot for mutations in human cancer(Simon A Forbes et al., 2015). The 
missense G290R variant is a likely SNP. It occurs in a tumor for which matched germline 
DNA is unavailable and it is predicted to be neutral, although it has not been previously 
described(Axelsson et al., 2013; Lindblad-Toh, Wade, Mikkelsen, Karlsson, Jaffe, 
Kamal, Clamp, Chang, Kulbokas, et al., 2005; Vaysse et al., 2011). In keeping with 
findings in other cancers, no sequence mutations were present in MDM2 and MDM2 
amplifications were mutually exclusive with TP53 mutations. Further, TP53 and MDM2 
alterations were mutually exclusive with RAS mutations in all but one case (ND10-748, 
Figure 1). 
 
Pathway dysregulation in canine melanoma. Common genomic subtypes of human 
cutaneous melanoma (BRAF, RAS (N/H/K), and NF1 in 90% of cases) that engage 
oncogenic signaling through the MAPK pathway are less common in human non-
cutaneous melanoma and in canine malignant melanoma (24% of cases here, Figure 1C). 
Therefore, to undertake unbiased identification of pathways contributing to canine 
melanomagenesis, we performed pathway analysis using WGS data from the discovery 
cohort. We generated a list of all genes bearing nonsynonymous mutations, lying within 
chromosomal breakpoints or significant CNV regions from GISTIC (n=1047) in order to 
determine enrichment of these mutated genes within specific KEGG and Reactome 
pathways (Materials and Methods)(Bindea et al., 2009; Croft et al., 2014; Kanehisa, 
Goto, Sato, Furumichi, & Tanabe, 2011). Network analysis of the affected genes 
identified 97 pathways with significant Benjamini-Hochberg corrected P-values 
(Supplementary Table 12). The most significantly enriched pathways were Insulin 
Receptor Substrate (IRS)-mediated signaling, and IRS-related events, for which 23% (19 
genes) of the pathway members are mutated in this cohort. Notably, these pathways 
converge on MAPK and PI3K mitogenic signaling and contain core pathway members 
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such as FGFs, EIF4G1, HRAS, KRAS, NRAS, and RPTOR. Indeed the majority of the 
enriched pathways contain members of MAPK, PI3K, or growth factor receptor signaling 
(e.g. PI3K cascade P=0.002, mTOR signaling P=0.008, signaling by Rho GTPases 
P=0.012, VEGF signaling P=0.017, RAF activation P=0.017, melanoma signaling 
P=0.021, RAS signaling P=0.031, and MEK activation P=0.036) and, in many cases, 
intersections with MDM2 signaling.  
 
DISCUSSION 
Melanoma is a clinically significant disease in dogs, the study of which holds untapped 
potential for developing clinical approached to improve the lives of pet dogs while also 
informing human melanoma biology and treatment. Few treatment options are available 
for locally advanced or metastatic canine melanoma in part because the molecular 
etiology is still largely unknown. Similarly, limited molecular understanding of rare sun-
shielded and BRAFwt subtypes of human melanoma has constrained clinical innovation. 
In order to identify the molecular alterations underlying canine melanoma, we undertook 
a comprehensive multi-platform genomic investigation. Our integrated analysis confirms 
that although these tumors are driven by mutational landscapes distinct from those in 
human cutaneous melanoma, they share important similarities with BRAFwt and rare 
histological subtypes of human melanoma. These data not only guide biological and 
therapeutic studies in canine melanoma, but they also lend further support for the use of 
the naturally occurring canine model in comparative studies of human cancers. 
This study builds on knowledge of the cytogenetic landscape of canine 
melanoma(Poorman et al., 2014) to provide a comprehensive view of numbers and types 
of somatic coding mutations in this cancer. Given the dearth of genomic data for canine 
melanoma, we initially focused here on collecting primary tumors from diverse breeds. 
Although numbers were too small to power such analyses, we saw no significant breed-
associated alterations in this cohort. Breed-specific somatic mutational landscapes have 
been shown to occur for other canine cancers such as lymphoma(Elvers et al., 2015). 
Future expanded study of breed-specific cohorts will be critical for further understanding 
the role of germline variation in shaping somatic cancer landscapes across species. It will 
also be important to further define subtype differences in expanded cohorts of canine 
acral and cutaneous tumors as well as benign and precursor lesions.  
Overall, the genomic landscapes of human melanoma vary by anatomic site and 
degree of sun exposure(Curtin et al., 2005; Hayward et al., 2017; Liang et al., 2017). 
Cutaneous sun-exposed melanoma is characterized both by high point mutation 
frequencies linked to UV damage(Berger et al., 2012) and also only modest burdens of 
structural variation. In contrast, sun-shielded and non-cutaneous melanomas harbor a low 
point mutation, but high structural mutation burden. Here, we establish that the canine 
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malignant melanoma genome landscape resembles that reported in human sun-shielded 
melanoma. Canine melanoma of all subtypes in our discovery cohort is likely sun-
shielded, including cutaneous tumors which occur in densely hair-bearing skin, although 
cropping or shaving during summer months may in some cases increase UV exposure. In 
keeping with this status, WGS in this cohort provides a deep view of genome-wide 
mutation burden revealing low point mutation frequencies (median 2.03 somatic 
mutations per Mb) similar to that seen in human acral and mucosal melanoma WGS data 
from Hayward et al. 2017 (Figure 3A)(Hayward et al., 2017). This low point mutation 
burden relative to human sun-exposed melanoma has potential bearing on expected 
responses to immunotherapy such as anti-CTLA4 and anti-PD1 checkpoint blockade. 
Numerous studies have shown a clear positive correlation between mutation burden, 
abundance of neoantigens, and clinical benefit in human melanoma and other 
cancers(Postow, Callahan, & Wolchok, 2015; Snyder et al., 2014). Nonetheless, other 
molecular determinants of response to immunotherapy exist beyond simply mutation 
burden and the activity of such agents in canine malignant melanoma remains to be 
determined. Notably, CNV and SV burden from our WGS in canine malignant melanoma 
was markedly lower than all subtypes as described in Hayward et al. (Figure 3B and 3C) 
(Hayward et al., 2017). 
WGS additionally provides a deep view of genome-wide mutation signatures. 
High point mutation burden in sun-exposed cutaneous melanoma is understood to result 
from UV-induced over-representation of C>T transitions occurring in dipyrimidines 
versus non-dipyrimidines. UV-induced C>T mutations occurring in dipyrimidines 
comprise a low proportion of total SNVs in our cohort (25%), reflective of human sun-
shielded cutaneous, mucosal and acral melanoma, in contrast to 85-90% of C>Ts 
occurring in dipyrimidines in human sun-exposed melanoma (Figure 3C)(Berger et al., 
2012; Simon J. Furney et al., 2013; Furney et al., 2014; Hayward et al., 2017; 
Krauthammer et al., 2012; Pleasance et al., 2010). This lends support for a non-UV 
etiology of canine melanoma. 
The genome-wide SNV spectrum further revealed that C>T transitions in CpGs 
were the most common sequence alterations (Supplementary Figure 2A). These 
mutations correlate with age in human cancers and are due to spontaneous deamination of 
5-methylcytosine(Alexandrov et al., 2013). Enrichment for these mutations in canine 
melanoma is not surprising given that the largest risk factor for cancer in humans and 
dogs is biological (not chronological) age(Albert, Benjamin, & Shukla, 1994; Cohen, 
Reif, Brodey, & Keiser, 1974; Dobson, Samuel, Milstein, Rogers, & Wood, 2002; Dorn, 
Taylor, Schneider, Hibbard, & Klauber, 1968; Merlo et al., 2008; Tomasetti, Vogelstein, 
& Parmigiani, 2013) and that the mean age of these dogs at the time of surgical resection 
was 13 years (range: 10 – 16). Relative to the average number of human somatic 
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mutations, these data provide further evidence that not only cancer incidence, but also 
mutational burden increases with biological, rather than chronological, age(Turker, 
2000). Commonly observed mutational patterns in human melanoma such as kataegis 
were not observed, although four tumors exhibited clustered or chained translocations 
suggestive of breakage-fusion-bridge events due to telomere crisis or of chromothripsis, 
in which one or a few chromosomes undergo punctuated shattering and reassembly 
events(Stephens et al., 2011). Such events have been linked to poor outcome in human 
melanoma(Hirsch et al., 2013) and may be enriched in tumors with p53 dysfunction or 
those that lack means to extend telomeres(Maher & Wilson, 2012; Rausch, Jones, et al., 
2012). Notably, we show here that MDM2 and mutually exclusive TP53 alterations are 
common in canine melanoma. Similarly, inactivating p53 mutations have been found in 
human mucosal and acral melanoma, suggesting p53 pathway dysregulation may be 
crucial in non-UV induced melanoma development. Further, UV-induced TERT promoter 
mutations are common in human cutaneous melanoma, and, although they are rare in 
sun-shielded subtypes, these subtypes have been shown to bear enrichment for other 
types of mutation that drive TERT overexpression such as SVs and CNVs(Liang et al., 
2017). The cutaneous tumors in this cohort do not bear somatic TERT promoter mutations 
or other known genetic lesions that would enable telomere extension. Thus, telomere 
crisis and the survival of structurally aberrant genomes may play a significant role in the 
molecular etiology of canine and non-UV induced human melanoma. 
Our comprehensive analysis of canine melanoma reveals that most canine 
melanomas bear a low coding mutation burden and are also less structurally complex 
than human melanoma. Two WGS approaches coupled with array-based platforms have 
enabled deep interrogation of these changes, complementing recent cytogenetic analyses 
of this tumor type(Poorman et al., 2014). Significant copy number gains on CFA10 and 
30 that have been reported as a defining signature of these lesions are recapitulated in this 
dataset (Supplementary Table 6). Our multi-platform approach was also able to further 
elucidate complex chromosomal rearrangements present in these regions. Both regions 
are involved in multiple intra- and inter-chromosomal structural events across this cohort 
(Supplementary Table 8). Additionally, focal amplification of the CFA10 10-12MB 
region encompasses MDM2, a gene which is known to drive human cancers and is 
currently being explored as a drug target in TP53 wild type tumors(Vassilev et al., 2004). 
CNVs associated with canine melanoma also include gain of CFA13 and loss of CFA22. 
While not statistically significant via GISTIC in this cohort, both events are present in 
individual samples. Overall, extensive copy number and structural variation suggest high 
levels of large-scale chromosome instability, i.e. gain and loss of whole chromosomes or 
chromosome arms. Intriguingly, mutually exclusive focal amplification of MDM2 or 
inactivating mutation in TP53 have been shown to be enriched in BRAF-, NRAS-, and 
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NF1-wild-type human melanoma, although human TP53-mutant melanomas tend to also 
display higher mutation burden and presence of C>T transitions(Network, 2015). Taken 
together the high degree of structural complexity, the lack of TERT mutations or 
telomere-lengthening mechanisms, and the frequency of MDM2/TP53 mutations all 
suggest that chromosome instability plays a key role in canine melanomagenesis.  
1 In the discovery cohort, putatively pathogenic somatic mutations in 
orthologs of human cancer genes were present in a single tumor each including ATF6, 
EPAS1, FAT2, FAT4, FOXA3, FOXO1, GAB2, HRAS, KIT, KRAS, MMP21, NRAS, 
PBX1, and XPO1 (Supplementary Table 3). Of the 14 melanoma hallmark genes 
evaluated in the prevalence cohort (including PTPRJ), an additional 24 putatively 
pathogenic somatic mutations were identified in seven genes – NRAS, TP53, PTPRJ, KIT, 
KRAS, GNA11, and BAP1 (Supplementary Table 4). Overall, across discovery and 
prevalence analyses, RAS gene family members were the genes most commonly bearing 
somatic SNVs, occurring in 24% of cases (Figure 1C and 2A), followed by TP53 and 
PTPRJ mutations each in 19% of cases, KIT in 8% and PTEN in 5%. Combined, these 
mutations most commonly impact proliferative and cell cycle/apoptosis pathways in 
patterns similar to those observed in human melanoma (Figure 3D). These findings also 
suggest that both MAPK pathway inhibition (via MEK inhibitors) or p53 pathway 
inhibition (via MDM2 inhibitors) may be of equal relevance in canine melanoma as they 
are in human(J. S. Fowles et al., 2013).  
The oncogenic MAPK pathway is critically important in many cancers given its 
central role in conveying extracellular signals to the nucleus in order to regulate cancer 
hallmarks including proliferation, invasion, metastasis, and angiogenesis. The majority of 
human cutaneous melanomas are driven in part by constitutive activation of the MAPK 
pathway through mutation of genes such as BRAF, NRAS, NF1, KIT, GNAQ, and GNA11, 
often in a mutually exclusive pattern(T. Zhang, Dutton‐Regester, Brown, & Hayward, 
2016). The high frequency of these mutations has motivated the TCGA classification of 
these tumors according to MAPK mutation status: BRAF (~50% of cases), RAS (~30%), 
NF1 (~15%), and TWT (~10%)(Network, 2015). These genomic categories are correlated 
with clinical, pathological, molecular, and biological features of melanoma and thus may 
comprise distinct subtypes. However, less common histological subtypes of melanoma 
such as mucosal, acral, and uveal melanoma bear unique mutation spectra that are not 
uniformly centered on canonical activating mutations in the MAPK pathway. 
Correspondingly, it has been shown that BRAF mutations are exceedingly rare in 
predominantly oral canine malignant melanoma and, to date, few alterations in other 
MAPK members have been discovered. These findings were recapitulated in our cohort, 
which showed no canonical BRAF or NF1 mutations. Nonetheless, MAPK and/or PI3K 
signaling have been shown to be activated in nearly all cases(R. Mark Simpson et al., 
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2013). Additional mutations impacting the MAPK and PI3K pathways include three KIT 
mutations, two PTEN mutations, and one GNA11 mutation. In total, 35% of mucosal and 
43% of all canine melanomas bear an alteration impacting the MAPK pathway (Figures 
1C and 3D). Prior to our studies described here, the mutations underlying such activation 
have remained largely unknown.  
Here we show a complete absence of somatic BRAF mutations (SNVs, CNVs, 
translocations, or fusions encompassing the BRAF locus) in canine malignant melanoma 
in keeping with prior studies(Gillard et al., 2014; Mochizuki et al., 2015; Poorman et al., 
2014; Shelly et al., 2005). We also did not uncover truncating SNVs in or homozygous 
deletions of NF1. A higher proportion of our cohort bear RAS mutations than the 6-13% 
previously described(Gillard et al., 2014; R. Mark Simpson et al., 2013), although prior 
studies have focused almost exclusively on NRAS exons one and two. All three major 
RAS family members are highly conserved (100% protein identity) between canine and 
human. In humans, of these family members, malignant melanomas predominantly bear 
NRAS mutations with only very rare KRAS and HRAS mutations. In our cohort, we found 
four NRAS codon 61 alterations (11%), four KRAS G12C mutations and one HRAS Q61R 
mutation. Further, four of these RAS alterations (two NRAS, one KRAS, and one HRAS 
mutation) occur in mucosal tumors, a frequency of 13% in this subtype. However, in our 
cohort all three acral tumors and both cutaneous tumors had detectable RAS alterations 
(three KRAS and two NRAS mutations). This unusual pattern of RAS mutation in canine 
melanoma may reflect important differences in biological, tissue, and species specificities 
of RAS family members.  
2 These data point to the genomic lesions underlying MAPK and PI3K 
activation in a substantial proportion of canine melanomas, and to subtle genetic 
differences in disease subtypes within and across species. Most striking is the discovery 
of a putative novel tumor suppressor gene, PTPRJ, a receptor-type protein tyrosine 
phosphatase, which has been genetically and functionally implicated in cancer (C. 
Ruivenkamp et al., 2003; C. A. Ruivenkamp et al., 2002), but for which clear genetic 
mechanisms of inactivation have yet to establish its definitive role as a canonical tumor 
suppressor gene. PTPRJ consists of an extracellular domain with eight fibronectin III 
motifs, a transmembrane domain, and an intracellular catalytic domain. It was originally 
cloned from HeLa cells and characterized by overexpression and hyper-activation in 
dense cultures of fibroblasts, by regulation of contact inhibition, and by its role in 
regulation of cancer cell proliferation and invasion(Balavenkatraman et al., 2006; Borges 
et al., 1996; Keane, Lowrey, Ettenberg, Dayton, & Lipkowitz, 1996; Ostman et al., 1994; 
Trapasso et al., 2000; Trapasso et al., 2004; L. Zhang et al., 1997). Early genetic studies 
of quantitative trait loci for mouse cancer susceptibility with homologous regions in 
human cancers pointed to recurrent PTPRJ deletions, LOH, and missense mutations in 
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small cohorts of colorectal (49%), lung (50%), and breast (78%) carcinomas in addition 
to a correlation between PTPRJ LOH and colorectal cancer progression(C. Ruivenkamp 
et al., 2003; C. A. Ruivenkamp et al., 2002). Additional sequencing studies in larger 
cohorts have identified nonsynonymous SNPs in the extracellular fibronectin repeats 
associated with risk of developing thyroid, colorectal, head and neck squamous cell, and 
esophageal cancers(Iuliano et al., 2004; Kovalenko et al., 2000; Lampugnani et al., 2003; 
Mita et al., 2010; Palka, Park, & Tonks, 2003)_ENREF_100. More recently, a subclonal 
K1017N missense mutation in the non-catalytic cytoplasmic domain of PTPRJ was 
identified in a primary breast tumor with significant enrichment in a brain metastases and 
patient-derived xenograft(Ding, Ellis, et al., 2010). PTPRJ substrates that may mediate its 
tumor suppressive potential include ERK1/2, Akt, various receptor tyrosine kinases, and 
Src kinases(Arora et al., 2011; Chabot, Spring, Gratton, Elchebly, & Royal, 2009; Sacco 
et al., 2009; K Spring et al., 2015; Kathleen Spring et al., 2014; Tarcic et al., 2009). 
However, Ptprj knockout mice have normal development with no cancer predisposition 
and thus inactivation of this gene does not appear to be sufficient to induce 
tumorigenesis(Trapasso et al., 2006). Across all TCGA studies published to date, the 
frequency of mutations and/or homozygous deletions appears to be low (400 altered 
cases), although truncating mutations have been found to comprise 31 of the 257 
mutations identified alongside 56 missense mutations predicted to be of medium or high 
impact (Supplementary Figure 9 and Supplementary Table 13)(Cerami et al., 2012; 
Gao et al., 2013). Only 10 mutations are present in the TCGA human cutaneous 
melanoma data set (a single homozygous deletion and nine missense mutations) with two 
missense mutations in desmoplastic melanoma and no detectable mutations in uveal 
melanoma. However, a related receptor-type protein tyrosine phosphatase, PTPRD, is 
thought play a role in regulation of STAT3 signaling and has been frequently implicated 
as a tumor suppressor in human cancers through inactivating somatic mutation, focal 
deletion or methylation in glioma, melanoma, neuroblastoma, colorectal, liver, head and 
neck, and lung cancers(Nair, DePreter, Vandesompele, Speleman, & Stallings, 2008; 
Solomon et al., 2008; Veeriah et al., 2009; Walia et al., 2014). In human cutaneous 
melanoma, PTPRD is deleted or truncated in 9-12% of cutaneous cases, but has not been 
determined to occur at high frequency in rare histological subtypes(Simon J. Furney et 
al., 2013; Furney et al., 2014; Solomon et al., 2008; M. Stark & Hayward, 2007; M. S. 
Stark et al., 2012).  
Here, we present the first report of recurrent somatic truncating mutations in 
PTPRJ in a naturally occurring cancer. We have discovered seven cases (19%) of canine 
melanomas bearing somatic PTPRJ mutations. Canine and human PTPRJ orthologs share 
70% sequence identity with a highly conserved C-terminus containing the protein 
tyrosine phosphatase catalytic domain (Supplementary Figure 6). Sequencing of PTPRJ 
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across all 38 tumors revealed nine mutations in seven cases (seven mucosal and one 
uveal) comprising 19% of all tumors and 23% of mucosal cases. Six frameshifts or stop 
gains were discovered in addition to one splice site mutation, a C-terminal 10-amino acid 
deletion, and a single predicted damaging missense mutation. Two cases – ND10-190 and 
ND10-376 – contained two mutations each, consistent with bi-allelic inactivation of a 
tumor suppressor gene. Further, loss of heterozygosity (LOH) was evident by analysis of 
adjacent SNPs in WGS data in case ND10-166 bearing the M110fs mutation 
(Supplementary Table 10). Although regional LOH on chromosome 18 was observed 
by SNP array in three of six cases bearing single mutations in PTPRJ, these regions were 
not observed to directly overlap the coding region of PTPRJ. Overall, the enrichment for 
PTPRJ truncating mutation in canine malignant melanoma bears intriguing implications 
both for a previously underappreciated role for this gene in human melanoma (e.g. 
through as-yet understudied roles for hemizygous deletion(Solimini et al., 2012) and/or 
epigenetic modifications) and for the possibility of unique mechanisms of tumorigenesis 
across species.  
Through deep integrated genomic analysis combining WGS, LI-WGS, RNA 
sequencing, aCGH, SNP arrays, and targeted Sanger sequencing we have determined that 
canine melanoma is driven by extensive chromosomal instability and frequent 
dysregulation of MAPK and cell cycle/apoptosis pathways. In keeping with prior 
comparative melanoma studies that have incorporated histology, targeted sequencing, and 
aCGH(J. S. Fowles et al., 2013; Gillard et al., 2014; Poorman et al., 2014; R Mark 
Simpson et al., 2014), this work highlights the striking resemblance of canine malignant 
melanoma to sun-shielded, BRAFwt subtypes of human melanoma. Finally, we have 
additionally discovered a putative novel tumor suppressor that may reflect unique 
species-specific biology and/or may highlight a tumor suppressive axis more subtly 
altered and as-yet underappreciated in human melanoma. This work bears immediate 
relevance for development of improved diagnostic and treatment approaches in canine 
malignant melanoma and provides further evidence to credential the naturally occurring 
canine melanoma model for study of relevant genomic subsets of human melanoma. 
 
MATERIALS AND METHODS 
Clinical samples, histopathology and sample assessment 
Tumor samples and whole blood were obtained under institutional review protocols at the 
Van Andel Research Institute in collaboration with local specialty veterinary clinics. 
Material was collected at surgery, immediately snap frozen, and preserved in optimal 
cutting temperature (OCT) compound. Patient matched control DNA was obtained from 
peripheral blood mononuclear cells. Each resected tumor was evaluated by a board 
certified pathologist (BD) to estimate tumor content and extent of tissue heterogeneity. 
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Diagnosis of malignant melanoma was histologically confirmed according to criteria 
defined by the American College of Veterinary Pathologists in addition to criteria 
recently established by comparative analyses of canine and human melanoma focusing on 
architecture, pigmentation, and the presence of differentiation markers(Gillard et al., 
2014; Goldschmidt, 1998; R. Mark Simpson et al., 2013). 
 
Immunohistochemistry 
Two tissue microarrays (TMAs), designated Dog MEL A TMA and Dog MEL B TMA, 
consisted of 96 individual dogs and 131 tissue samples placed in duplicate and two tissue 
samples placed in quadruplicate (272 array spots). Multiple tumors from nine dogs were 
present on the array and multiple samples from varying sites within the same tumor were 
present for twelve dogs. Additionally, non-melanoma stromal or control normal tissues 
were included. TMAs were H&E-stained and evaluated via routine immunohistochemical 
procedures for melanoma cocktail (anti-melan A, anti-melanosome, and anti-tyrosinase), 
and antibodies to vimentin, MDM2 and p53. Samples scoring positive for MDM2 
staining were then confirmed for positive staining with melanoma cocktail and re-
evaluated for p53 staining. Positive staining was counted if at least one of the two 
duplicate samples could be evaluated for both MDM2 and melanoma cocktail on the 
TMA. Antibodies were purchased from Santa Cruz Biotechnology or Cell Marque. A 
total of 98 dogs and 189 spots/samples (132 tumors) met these criteria for evaluation for 
MDM2 protein expression by IHC. Of these 98 dogs, 18 dogs (17%) had melanocytic 
tumors positive for MDM2 staining in 33 spots/samples (25%). MDM2 staining was 
predominantly cytoplasmic highest intensity at junction between epithelial and 
subepithelial (submucosa, dermis). Staining was observed in both malignant pigmented 
and amelanotic melanoma and benign melanocytomas. Most intense staining (4+ 
cytoplasmic and nuclear) was observed in a benign cutaneous melanocytoma from a 
boxer that had additionally a malignant melanoma (negative for MDM2 staining on the 
array) and multiple cutaneous mast cell tumors. 
 
Nucleic acid extraction from tumor tissue and blood 
Tissue was disrupted and homogenized in Buffer RLT plus (Qiagen AllPrep DNA/RNA 
Mini Kit), using the Bullet Blender™, Next Advance, and transferred to a 
microcentrifuge tube containing Buffer RLT plus and 1.6 mm stainless steel beads or 0.9 
mm–2.0 mm RNase free stainless steel beads. Blood leukocytes (buffy coat) were 
isolated from whole blood by centrifugation at room temperature and resuspended in 
Buffer RLT plus. All samples were homogenized, centrifuged at full speed, and lysates 
were transferred to Qiagen AllPrep spin columns. Genomic DNA and RNA were then 
purified following the manufacturer's protocol. DNA was quantified using the Nanodrop 
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spectrophotometer and quality was accessed from 260/280 and 260/230 absorbance 
ratios. RNA was analyzed on the Agilent Bioanalyzer RNA 6000 Nano Chip to validate 
RNA integrity (RIN≥7.0). 
 
Library construction and next generation sequencing 
Three µg of genomic DNA from each sample was fragmented to a target size of 300–350 
base pairs (bp). Overhangs in the fragmented samples were repaired and adenine bases 
were ligated on. Diluted paired end Illumina adapters were then ligated onto the A-tailed 
products. Following ligation, samples were run on a 3% TAE gel to separate products. 
Ligation products at 300 bp and 350 bp were selected for each sample, isolated from gel 
punches, and purified. 2× Phusion High-Fidelity PCR Master Mix (Finnzymes; 
catalog#F-531L) was used to perform PCR to enrich for these products. Enriched PCR 
products were run on a 2% TAE gel and extracted. Products were quantified using 
Agilent's High Sensitivity DNA chip (catalog#5067-4626) on the Agilent 2100 
Bioanalyzer (catalog#G2939AA). 
Long insert whole genome libraries were constructed as previously described(W. 
S. Liang et al., 2014) with the following modifications: 1100ng inputs were used; 
following DNA fragmentation, a bead purification was performed at a 1:1.8 (sample 
volume: bead volume) ratio; a 1% size selection gel was used; and during library 
enrichment, 10 PCR cycles was used. Libraries were clustered onto Illumina V3 flowcells 
(San Diego, CA) using Illumina’s TruSeq PE Cluster Kit V3 (cat#PE-401-3001) and 
sequenced for paired 100bp reads using Illumina’s TruSeq SBS Kit V3 (cat#FC-401-
3002, n=3) on the Illumina HiSeq. 
10 ng of total RNA was used to generate whole transcriptome libraries for RNA 
sequencing. Using the Nugen Ovation RNA-Seq System (cat#7100-08), total RNA was 
used to generate double stranded cDNA, which was amplified using Nugen's SPIA linear 
amplification process. Amplified cDNA was input into Illumina's TruSeq DNA Sample 
Preparation Kit – Set A (cat#FC-121-1001) for library preparation. In summary, 1 µg of 
amplified cDNA was fragmented to a target insert size of 300 bp and end repaired. 
Samples were then adenylated and indexed paired end adapters were ligated. Ligation 
products were run on a 2% TAE gel and size selected at 400 bp. Ligation products were 
isolated from gel punches and purified. Cleaned ligation products were input into PCR to 
enrich for libraries. PCR products were cleaned and quantified using the Agilent 
Bioanalyzer. 
Tumor and normal libraries were prepared for paired end sequencing as described 
above. Clusters were generated using Illumina's cBot and HiSeq Paired End Cluster 
Generation Kits (catalog#PE-401-1001) and sequenced on Illumina's HiSeq 2000 using 
Illumina's HiSeq Sequencing Kit (catalog#FC-401-1001).  
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Next generation sequencing data analysis 
BCL to FASTQ file conversion was performed using Illumina's BCL converter tool. 
Read alignment was performed with BWA (Burrows-Wheeler Aligner)(Uva et al., 2009) 
using the canine reference genome CanFam 3.1. Aligned BAMs were indel 
(insertion/deletion) realigned and recalibrated using GATK(Aaron McKenna et al., 2010; 
Geraldine A Van der Auwera et al., 2013) and duplicate pairs marked using Picard 
(http://broadinstitute.github.io/picard/). Variants were called using Strelka(Saunders et 
al., 2012b), Seurat(A. Christoforides et al., 2013) and MuTect(K. Cibulskis et al., 2013) 
and calls were annotated according to dbSNP 139, SNPs on the Illumina CanineHD 
BeadChip, and SnpEff-3.5(Pablo Cingolani et al., 2012). Final somatic SNVs were called 
by at least 2/3 callers. LI-WGS data were utilized for CNV and SV detection. For CNV 
detection, read depths at every 100 bases across sequenced regions were determined. 
Next, normalized log2 fold-changes between tumor and normal were calculated and a 
smoothing window applied. Tumor allele frequencies of known heterozygous germline 
SNPs were utilized to evaluate potential false positives and correct biases. Finally, the 
Circular Binary Segmentation algorithm(Olshen, Venkatraman, Lucito, & Wigler, 2004) 
was used to correct log2 fold-changes. For mutation burden metrics, a focal CNV is 
included if the log2 change is >=|2|. SV detection was performed utilizing Delly(Rausch, 
Zichner, et al., 2012). A minimum tumor allele ratio of 0.10 and a minimum quality score 
of 20 is required for an SV to be called. 
RNA sequencing data in FASTQ format from the Illumina HiSeq was checked for 
quality using cycle-by-cycle quality plots and biases, such as GC content. Reads were 
aligned to the canine reference genome CanFam 3.1 using the TopHat spliced aligner to 
generate alignment files in BAM format_ENREF_40(Trapnell, Pachter, & Salzberg, 
2009)_ENREF_99_ENREF_84. These data were utilized for validation of expressed 
sequence variants in IGV. Gene fusions were also identified in RNAseq data using the 
TopHat-Fusion software package(Daehwan Kim & Steven L Salzberg, 2011) and IGV 
verification. Results were reported in tables showing p-values (adjusted for multiple 
testing) and normalized abundance data in terms of FPKM (fragments per kilo-base of 
transcript per million mapped reads) which were also examined manually. Gene and 
transcript annotations were downloaded from ENSEMBL (CanFam 3.1.68) and germline 
SNPs filtered out using publicly available canine SNP data (71-73). 
 
Data access 
Next generation sequencing data from this study have been submitted to the NCBI 
Biosample Database (http://www.ncbi.nlm.nih.gov/biosample/7196161) under study ID 
SUB2752127 and accession numbers SAMN07196161, SAMN07196162, 
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SAMN07196163, SAMN07196164, SAMN07196165, SAMN07196166, and 
SAMN07196167. 
 
Pathway analysis 
A list of 1,405 genes with single nucleotide variation or structural variation or copy 
number variation from the discovery cohort were analyzed using ClueGo4(Bindea et al., 
2009), a Cytoscape plug-in, to create a functionally organized pathway network. Kappa 
scores were then used to measure association between the networks. Functional networks 
were created with a minimum Kappa score threshold of 0.5 and a minimum of 3 affected 
genes in every network forming at least 10% of the total associated genes in that 
particular network. The genes were assigned to the networks based on the predefined 
pathways from KEGG, REACTOME and Wiki Pathways. 97 pathways were obtained, all 
with Benjamini-Hochberg corrected P-value <0.05. These pathways were grouped 
together based on inter-term kappa score and named by the most significant pathway in 
the respective groups. 
 
PCR amplification and Sanger sequencing analysis 
PCR amplification of 15 genes (NRAS, KRAS, BRAF, GNA11, GNAQ, PTPRJ, TP53, 
MDM2, BAP1, CDK4, PTEN, c-KIT, MITF and NF1) was performed using 
primers_ENREF_86 targeting all coding exons as shown in Supplementary Table 9. All 
amplification reactions were performed using Platinum Taq DNA Polymerase #10966-
034 (Life Technologies; Carlsbad, CA). Briefly, each primer pair was mixed with 10 ng 
of genomic DNA and subjected to the following cycling parameters: 94°C for 2 min., 3 
cycles at each temperature: 30 sec. at 94°C, 30 sec. at 60-57°C, 45 sec. at 72°C; 25 
cycles: 30 sec. at 94°C, 30 sec. at 62°C, 45 sec. at 72°C; final extension of 5 min. at 
72°C. PCR amplicons were sequenced using M13 forward and reverse primers at the 
Arizona State University’s DNA Lab (Tempe, AZ). 
 
Array comparative genomic hybridization 
Oligo array CGH (aCGH) was performed by co-hybridization of tumor (test) DNA and a 
common reference DNA sample, where the latter comprised an equimolar pool of 
genomic DNA samples from multiple healthy individuals of various breeds. DNA was 
labeled using an Agilent SureTag Labeling Kit (Agilent Technologies, Santa Clara, CA) 
with all test samples labeled with Cyanine-3-dCTP and the common reference sample 
labeled with Cyanine-5-dCTP. Fluorochrome incorporation and final probe 
concentrations were determined using routine spectrophotometric parameters with 
readings taken from a Nanodrop1000. Fluorescently labeled test and reference samples 
were co-hybridized to Canine G3 180,000 feature CGH arrays (Agilent, AMADID 
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025522) for 40 h at 65 °C and 20 rpm, as described previously(Angstadt, Thayanithy, 
Subramanian, Modiano, & Breen, 2012; Thomas et al., 2014). Arrays were scanned at 3 
µm using a high-resolution microarray scanner (Agilent,Model G2505C) and data 
extracted using Feature Extraction (v10.9) software. Scan data were assessed for quality 
by the ‘Quality Metrics’ report in Agilent’s Feature extraction software (v10.5) (Agilent 
Technologies).  
 
SNP array genotyping 
SNP genotyping was performed using the Illumina CanineHD array (cat#WG-440-1001).  
Per manufacturer’s protocol, 200ng of DNA was first denatured then neutralized with 
0.1N NaOH before amplification at 37°C for 24 hours. The amplified DNA was then 
enzymatically fragmented and precipitated using 100% 2-propanol before drying for one 
hour at room temperature. After resuspension the fragmented DNA was then denatured 
and loaded onto the CanineHD BeadChip and hybridized for 16 hours at 48°C. 
BeadChips were washed, a single base extension of hybridized primers added followed 
by multi-layer staining of the primers. Arrays were then washed, coated with the XC4 
reagent (Illumina) and dried under vacuum for one hour. Coated arrays were read on the 
HiScan system and data visualized using the Illumina Genome Studio Genotyping 2.0 
software with an average sample call rate of 97%.  
 
aCGH and SNP array data analysis 
For both aCGH and SNP arrays, copy number data were analyzed with NEXUS Copy 
Number v8.0 software (Biodiscovery Inc., CA, USA). For cross-platform comparisons, 
LI-WGS BAMs were also analyzed utilizing Nexus software. CNVs were identified 
using a FASST2 segmentation algorithm with a significance threshold of 5.5×10−6. 
Aberrations were defined as a minimum of three consecutive probes with log2 tumor: 
reference value of >1.14 (high gain), 1.13 to 0.2 (gain), −0.23 to −1.1 (loss), <−1.1 (big 
loss). Recurrent CNVs within each subtype were determined within NEXUS using an 
involvement threshold of 50 %. Significance of these regions was then determined in 
NEXUS using the GISTIC algorithm (to identify regions with a statistically high 
frequency of CNVs over background) with a G-score cut off of G>1.0 and a significance 
of Q<0.05. CNV frequency comparisons amongst sample groups were performed in 
NEXUS using Fisher’s exact test with differential threshold of >50 % and significance 
p<0.05. Significance of each probe between the two groups was calculated in NEXUS 
using a Mann–Whitney test for median comparison.
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FIGURE 1 THE MUTAITON LANDSCAPE OF CANINE MELANOMA 
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FIGURE 2: RECURRENT SOMATIC ALTERATIONS IN CANINE 
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FIGURE 3: KEY DISREGULATED PATHWAYS IN CANINE AND HUMAN 
MELANOMA 
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SUPPLEMENTARY FIGURE 2: MUTATION SPECTRUM IN CANINE 
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SUPPLEMENTARY FIGURE 3: CIRCOS PLOTS OF DISCOVERY COHORT 
 
 
154 
 
 
 
 
 
155 
 
SUPPLEMENTARY FIGURE 4: CNV CONCORDANCE PLOTS 
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SUPPLEMENTARY  FIGURE 5: HUMAN AND CANINE KIT ALIGNMENT 
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SUPPLEMENTARY FIGURE 6: HUMAN AND CANINE PTPRJ ALIGNMENT 
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SUPPLEMENTARY FIGURE 7: MDM2 STAINING IN CANINE MELANOMA 
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Appendix 5 is reproduced from “Somatic inactivating PTPRJ mutations and dysregulated 
pathways identified in canine melanoma by integrated comparative genomic analysis” 
(Hendricks et al., 2017), that was published in BioRxiv and I am one of the first listed co-
authors. This article is published under an open access license (CC-BY-NC-ND) that 
permits unrestricted use, dristribution and reproduction of the article. All co-authors 
granted their permission for the reproduction of the work for this dissertation.  
 
 
